BerGenBio ASA  
 Jonas Lies vei [ADDRESS_1084391]  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084392]:  Bemcentinib ( BGB324 ) 
Protocol Number:  BGBC003  
Phase  Phase I b/II 
Protocol Title:  An open label, multicenter , phase Ib/II study of BGB324  
(bemcentinib)  administered as a single agent or in 
combination with cytarabine or decitabine in patients with 
acute myeloid leukemia or as a single agent in patients with 
myelodysplastic syndrome   
EudraCT Number:  2014 -000165 -46 
IND Number:  124255  
Version and Date:  10.0 (US); 14 July 2021  
  
  
  
 
 
This study will be conducted in compliance with International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)  
guidelines on Good Clinical Practice (GCP), the Declaration of Helsinki (with 
amendments), and in accordance with local legal and regulatory requirements  
 
 
 
CCI
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 2 of 131 
 1. Protocol Approval Signatures  
Protocol BGBC003 Version 10.0 (US), 14 July 2021  
Sponsor’s Approval:  
This protocol has been approved by [CONTACT_144273] A 
Signature:  
 [CONTACT_1782]:  
[CONTACT_788006]’s Approval:   
I, the undersigned, have reviewed the Protocol, including Appendices and I will conduct 
the BGBC003 clinical study as described and in accordance with International Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use  
(ICH)  guidelines on Good Clinical Practice (GCP) and all the ethical and regulatory 
considerations stated . I have read and understood the contents of the bemcentinib 
Investigator’s Brochure  
Signature:  [CONTACT_1782]:  
  
 
 
 
 
  
  
[COMPANY_003]
[COMPANY_003]
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084393] details for each Investigational site, the Sponsor and other key coordinating and 
operational personnel involved in this clinical trial (including vendors), are maintained and 
available for reference in each Site Study File and in the Trial Master File.  
 
 
  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084394] ion ................................ ................................ ..............................  32 
7.1.  Pre-clinical Studies with Bemcentinib  ................................ .......................  32 
7.1.1.  Summary of Pre -clinical Activity  ................................ ...............................  32 
7.1.2.  Summary of Pre -clinical Toxicology  ................................ .........................  33 
7.1.3.  High Dose Steroids and Mouse Model  ................................ .....................  34 
7.2.  Clinical Studies with Bemcentinib  ................................ .............................  34 
7.2.1.  Summary of Clinical Safety  ................................ ................................ ...... 35 
[IP_ADDRESS].  ECG Findings  ................................ ................................ ...........................  35 
7.2.2.  Summary of Clinical Pharmacokinetics  ................................ ....................  36 
7.2.3.  Selection of the Starting Dose for Clinical Study  BGBC003  .....................  37 
[IP_ADDRESS].  Formulation 1 and Formulation 2  ................................ .............................  40 
8. Study Objectives and Endpoints  ................................ ..............................  41 
8.1.  Objectives  ................................ ................................ ................................  41 
8.1.1.  Primary Objectives  ................................ ................................ ...................  41 
8.1.2.  Secondary Objectives  ................................ ................................ ..............  41 
8.1.3.  Exploratory Objectives  ................................ ................................ .............  42 
8.2.  Endpoints  ................................ ................................ ................................ . 42 
8.2.1.  Safety Endpoints  ................................ ................................ ......................  42 
8.2.2.  Efficacy Endpoints  ................................ ................................ ....................  42 
8.2.3.  Pharmacokinetic Endpoints  ................................ ................................ ...... 43 
8.2.4.  Pharmacodynamic and Predictive Endpoints  ................................ ...........  43 
9. Study Design  ................................ ................................ ............................  45 
9.1.  Overview  ................................ ................................ ................................ .. 45 
9.2.  Study Specifics  ................................ ................................ .........................  47 
9.2.1.  Phase I DLT Assessment Period  ................................ .............................  47 
[IP_ADDRESS].  Dose Escalation Scheme  ................................ ................................ .........  48 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 5 of 131 
 [IP_ADDRESS].  Dose Limiting Toxicity  ................................ ................................ ..............  49 
9.2.2.  Part B  ................................ ................................ ................................ ....... 50 
9.3.  Overall Study Duration and Follow Up  ................................ .....................  50 
9.3.1.  Screening  ................................ ................................ ................................ . 51 
9.3.2.  Treatment  ................................ ................................ ................................ . 51 
9.3.3.  Final Study Visit  ................................ ................................ .......................  52 
9.3.4.  Follow Up  ................................ ................................ ................................ . 52 
9.4.  Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ...............  53 
9.5.  End of Study  ................................ ................................ .............................  53 
10. Selection of Subjects  ................................ ................................ ................  55 
10.1.  Inclusion Criteria  ................................ ................................ ......................  55 
10.2.  Exclusion Criteria  ................................ ................................ .....................  56 
11. Study Procedures and Assessments  ................................ .......................  60 
11.1.  Enrolment  ................................ ................................ ................................ . 69 
11.1.1.  Blinding Procedures  ................................ ................................ .................  69 
11.2.  Screening  ................................ ................................ ................................ . 69 
11.3.  Treatment Period  ................................ ................................ .....................  70 
11.3.1.  Part A  ................................ ................................ ................................ ....... 70 
[IP_ADDRESS].  Cycle 1  ................................ ................................ ................................ ..... 70 
[IP_ADDRESS].  Cycle 2 ................................ ................................ ................................ ..... 73 
[IP_ADDRESS].  Cycle 3 and Subsequent Cycles  ................................ ..............................  74 
11.3.2.  Parts B1 and B4  ................................ ................................ .......................  74 
[IP_ADDRESS].  Cycle 1  ................................ ................................ ................................ ..... 75 
[IP_ADDRESS].  Cycle 2 ................................ ................................ ................................ ..... 77 
[IP_ADDRESS].  Cycle 3 and Subsequent Cycles  ................................ ..............................  78 
11.3.3.  Part B2, Part B3 and Part B5  ................................ ................................ ... 78 
[IP_ADDRESS].  Cycle 1  ................................ ................................ ................................ ..... 79 
[IP_ADDRESS].  Cycle 2 ................................ ................................ ................................ ..... 81 
[IP_ADDRESS].  Cycle 3 and Subsequent Cycles  ................................ ..............................  82 
11.4.  Final Study Visit  ................................ ................................ .......................  83 
11.5.  Survival Follow -up ................................ ................................ ....................  84 
12. Treatment of Subjects  ................................ ................................ ..............  85 
12.1.  Treatment Schedule and Administration  ................................ ..................  85 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084395] Symptomatology ................................ ................................ ..........  93 
13.2.  Laboratory Safety Assessments  ................................ ...............................  93 
13.2.1.  Hematology and Clinical Chemistry  ................................ .........................  93 
13.2.2.  Urinalysis  ................................ ................................ ................................ .. 94 
13.3.  Pharmacokinetic Assessments  ................................ ................................  94 
13.3.1.  Determination of Bemcentinib Concentration in Plasma  ..........................  95 
13.4.  Clinical Efficacy Assessments  ................................ ................................ .. 95 
13.5.  Pharmacodynamic and Predictive Biomarkers  ................................ .........  96 
13.5.1.  Bone Marrow Aspi[INVESTIGATOR_4026]  ................................ ................................ ............  97 
13.5.2.  Pharmacodynamic Blood Samples  ................................ ..........................  97 
13.6.  Volume of Blood and Bone Marrow Sampling  ................................ ..........  98 
14. Study Treatment Management  ................................ ................................ . 99 
14.1.  Study Medication  ................................ ................................ ......................  99 
14.1.1.  Bemcentinib  ................................ ................................ .............................  99 
[IP_ADDRESS].  Bemc entinib Storage  ................................ ................................ ................  99 
[IP_ADDRESS].  Bemcentinib Accountability  ................................ ................................ ...... 99 
14.1.2.  Cytarabine and Decitabine  ................................ ................................ ..... 100  
[IP_ADDRESS].  Cytarabine and Decitabine Storage  ................................ .......................  101  
[IP_ADDRESS].  Cytarabine and Decitabine Accountability  ................................ ..............  101  
15. Safety Definitions, Monitoring and Reporting  ................................ .........  102  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 7 of 131 
 15.1.  Definitions  ................................ ................................ ..............................  102  
15.1.1.  Adverse Event  ................................ ................................ ........................  102  
15.1.2.  Adverse Reaction  ................................ ................................ ...................  103  
15.1.3.  Serious Adverse Event  ................................ ................................ ...........  103  
15.2.  Monitoring and Reporting Events  ................................ ...........................  104  
15.2.1.  Adverse Events  ................................ ................................ ......................  104  
15.2.2.  Serious Adverse Events  ................................ ................................ .........  104  
15.2.3.  All Events  ................................ ................................ ...............................  105  
15.3.  Safety Classifications  ................................ ................................ .............  105  
15.3.1. Assessment of Severity  ................................ ................................ ..........  105  
15.3.2.  Assessment of Causality  ................................ ................................ ........  105  
15.3.3.  Assessment of Expectedness  ................................ ................................  106  
15.3.4.  Immediate Reporting of Serious Adverse Events  ................................ ... 106  
15.3.5.  Annual Safety Updates  ................................ ................................ ..........  107  
15.3.6.  Deaths  ................................ ................................ ................................ .... 107  
15.3.7.  Procedures for Handling Special Situations  ................................ ...........  107  
[IP_ADDRESS].  Pregnancy  ................................ ................................ ..............................  107  
15.3.8.  Medi cal Emergency  ................................ ................................ ................  108  
[IP_ADDRESS].  Unblinding for a Medical Emergency  ................................ ......................  108  
15.4.  Investigator’s Safety Responsibilities  ................................ .....................  108  
15.5.  Sponsor’s Safety Responsibilities  ................................ ..........................  109  
15.6.  Overdose  ................................ ................................ ................................  109  
16. Statistical Methods and Determination of Sample Size  ..........................  110  
16.1.  Description of Objectives  ................................ ................................ ........  110  
16.2.  Description of Endpoints  ................................ ................................ ........  110  
16.3.  Demography and Baseline Disease Characteristics  ..............................  110  
16.4.  Safety  ................................ ................................ ................................ ..... 111  
16.4.1.  Analysis Population  ................................ ................................ ................  111  
16.4.2. Methods of Analysis  ................................ ................................ ...............  111  
16.5.  Efficacy ................................ ................................ ................................ ... 112  
16.5.1.  Analysis Population  ................................ ................................ ................  112 
16.5.2.  Methods of Analysis  ................................ ................................ ...............  112  
16.6.  Pharmacokinetics  ................................ ................................ ...................  113  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084396] Research Organisations  ................................ ..........................  120  
18.8.  Changes to the Final Study Protocol  ................................ ......................  120  
18.9.  Investigator Responsibilities  ................................ ................................ ... 120  
19. References  ................................ ................................ .............................  122  
20. Appendices  ................................ ................................ ............................  123  
Appendix 1:  Easte rn Cooperative Oncology Group (ECOG) Performance Status  123  
Appendix 2:  The [LOCATION_001] Heart Association (NYHA) Functional Classifica tion in a 
Patient with Heart Disease  ................................ ................................  124  
Appendix 3:  Drugs Associated with a Risk of QT Prolongation and Cardiac 
Arrhythmias  ................................ ................................ .......................  125  
Appendix 4:  CYP3A4 Substrates  ................................ ................................ ..........  127  
Appendix 5:  Modified International Working Group Response Criteria in Acute 
Myeloid Leukemia (Cheson, 2003, Döhner, 2017)  ............................  128  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 9 of 131 
 Appendix  6: International Working Group Response Criteria in Myelodysplastic 
Syndromes (Cheson, 2006)  ................................ ..............................  129  
 
  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084397] of Tables  
 
Table 1:  Bemcentinib Kinase Selectivity Profile  ................................ .......................  32 
Table 2:  Bemcentinib -Related Adverse Events Reported Following a Single Oral 
Administration of Bemcentinib (50 mg to 1500 mg) to Healthy Male 
Subjects  ................................ ................................ ................................ ..... 35 
Table 3:  Possible Bemcentinib Dosing Levels Involving A Loading Dose and Daily 
Dose for Part A  ................................ ................................ ..........................  48 
Table 4:  Part A Schedule of Events  ................................ ................................ .........  61 
Table 5:  Parts B1 and B4 Schedule of Events  ................................ .........................  63 
Table 6:  Parts B2, B3 and B5 Schedule of Events  ................................ ..................  66 
Table 7:  Dose Modification of Bemcentinib Daily Dose for Toxicity  .........................  87 
Table 8:  Dose Modification of Bemcentinib Daily Dose for QTc Prolongation  .........  88 
Table 9:  Hematology, Clinical Chemistry and Coagulation Parameters  ..................  93 
Table 10: Urinalysis  Parameters  ................................ ................................ ..............  94 
Table 11: Bemcentinib PK Sampling Time Points and Permitted Windows  .............  94 
Table 12: Volume of blood and BM aspi[INVESTIGATOR_787899] 1  ................................ ................................ ..........  98 
Table 13: Volume of Blood and BM aspi[INVESTIGATOR_787900] 2
 ................................ ................................ ................................ ..................  98 
Table 14: Volume of Blood and BM aspi[INVESTIGATOR_787901] >3 (up 
to and including Cycle 15 for PK and Blood Pharmcodynamics) & at Final 
Study Visit  ................................ ................................ ................................ . 98 
Table 15: Plasma PK parameters  ................................ ................................ ..........  113 
Table 16: Operating Characterist ics of the 3+[ADDRESS_1084398] of Figures  
Figure 1: Mean Plasma Co BGBC003 Protocol v10.0 (US) dated 
14July2021_tracked ncentrations of Bemcentinib Following a Single Oral 
Administration of Bemcentinib at 50, 100, 150, 200, 400, 600, 1000 and 
1500 mg to Healthy Male Subjects  ................................ ............................  36 
Figure 2: Simulated Plasma Concentrations of Bemcentinib for 600 mg Loading 
Dose on Days 1 and 2 and Daily Dose of 200 mg from Day 3 (fed)  ..........  38 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 11 of 131 
 Figure 3: Simulated Plasma Concentrations of Bemcentinib for 600 mg Loading 
Dose on Days 1 and 2 and Daily Dose of 200 mg from Day 3 (fasted)  ..... 39 
Figure 4: Predicted Plasma Concentrations of Bemcentinib after 1200 mg Loading 
Dose Given as 600 mg on Days 1 and 2 or 400 mg on Days 1, 2  and 3, 
followed by [CONTACT_787960] 200 mg (fasted)  ................................ ................  39 
Figure 5: BGBC003 Study Design  ................................ ................................ ............  47 
Figure 6: The 3+3 Dose Escalation Design  ................................ ..............................  49 
  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084399] Aspartate aminotransferase  
AUC 0-∞ Area under the curve from time zero to infinity  
AUC 0-48h Area under the curve from time zero to [ADDRESS_1084400] Research Organi zation  
CSR  Clinical study report  
CTCAE  Common Terminology Criteria for Adverse Events  
CTD Clinical Trials Directive  
CV Cardiovascular  
DHA  Directions for Handling and Administration  
DLT Dose limiting toxicity  
DSUR  Development Safety Update Report  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Form 
EDC  Electronic data capture  
EU European Union  
FCM  Flow cytometry  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
h Hour  
hERG  Human ether -à-go-go related gene  
HIV Human immunodeficiency virus  
HPMC  Hydroxypropyl methylcellulose  
HR Heart rate  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH  International Council for Harmonisation  
IDMC  Independent Data Monitoring Committee  
IMP Investigational medicinal product  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084401]  
IWG International Working Group  
K Potassium  
LC/MS/MS  Liquid chromatography/tandem mass spectrometry  
LDAC  "Low -dose” cytarabine  
MCH  Mean cell hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MDS  Myelodysplastic syndrome  
MedDRA  Medical Dictionary for Regulatory Activities  
MTD  Maximum tolerated dose  
MUGA  Multi Gated Acquisition Scan  
Na Sodium  
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for 
Adverse Events  
NSCLC  Non-small cell lung cancer  
NYHA  [LOCATION_001] Heart Association  
OR Objective response  
ORR  Objective response rate  
OS Overall Survival  
pAXL  Phospho AXL  
PBMC  Peripheral blood mononuclear cell(s)  
PCR  Polymerase chain reaction  
PD Progressive Disease  
PII Personally identifiable information  
PK Pharmacokinetic  
PR Partial Remission  
PT Prothrombin time  
QA Quality Assurance  
QTcF  QTc interval according to Fridericia’s correction  
REC  Research Ethics Committee  
RP2D  Recommended Phase [ADDRESS_1084402] characteristics  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
T½ Terminal half -life 
TdP Torsade de Pointes  
TEAE  Treatment Emergent Adverse Events  
Tmax Time to maximum concentration  
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084403] Upper limit of normal  
WT Wild Type  
 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 15 of 131 
 6. Protocol Synopsis  
PROTOCOL TITLE:  An open label, multicent er, phase Ib/II study of BGB324  
(bemcentinib)  administered as a single agent or in 
combination with cytarabine or decitabine in patients with 
acute myeloid leukemia or as a single agent in patients 
with myelodysplastic syndrome   
PROTOCOL No:  BGBC003  
SPONSOR:  BerGenBio AS A, Jonas Lies vei 91, 5009, Bergen,  
Norway  
INVESTIGATIONAL 
PRODUCT:  Bemcentinib (BGB324 ) 
PHASE OF DEVELOPMENT:  Phase I b/II 
INDICATION AND 
RATIONALE:  Acute myeloid leukemia (AML) (with the exception of 
AML M3)  and myelodysplastic syndrome (MDS)  with the 
exception of deletion 5q MDS.  
This is the first clinical study of bemcentinib in patients.  
Bemcentinib is a potent selective small molecule inhibitor 
of AXL, a surface membrane protein receptor tyrosine 
kinase which is overexpressed in up to half  of AML 
cases . AXL expression has been identified as a marker 
of a poor prognosis in AML. In vitro  studies indicate that 
signaling through AXL stimulates a number of pro -
survival pathways some of which are mediated by [CONTACT_787961] -regulation of the epi[INVESTIGATOR_787902]. In vitro  studies indicate that 
activation of AXL enables malignant cells to develop 
resistance to c onventional chemotherapi[INVESTIGATOR_014]. Preliminary 
in vitro  studies using AML cell lines indicate that 
treatment with bemcentinib is at least additive in effect 
when administered with cytarabine).  Early in vitro  and ex 
vivo studies also indicate that AXL inhibition w ith 
bemcentinib inhibits proliferation of mononucleated bone 
marrow (BM)  derived from patients with MDS.  
OBJECTIVES:  Part A  
PRIMARY  
• To identify the maximum tolerated dose (MTD) of 
bemcentinib in AML patients who have received 
previous treatment with cytotoxic chemotherapy 
(with or without hematopoietic stem cell 
transplantation) or a targeted or biologic agent 
(e.g. hypomethylating agent, tyrosine kinase 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 16 of 131 
 inhibitor, antibody) , and have relapsed after or 
have been refractory to treatment with such prior 
therapy  
SECONDARY  
• To identify the dose limiting toxicity (DLT) profile 
of bemcentinib  
• To explore the safety and efficacy of bemcentinib  
• To characteri ze the pharmacokinetic (PK) profile 
of bemcenti nib  
Part B  
PRIMARY  
• To identify the safety and tolerability of 
bemcentinib as a single agent in patients with 
AML or MDS (Parts B1 and B4), in combination 
with low dose cytarabine in patients with AML 
(Part B2  and Part B5 ), or in combination with 
decitabine in patients with AML (Part B3)  
SECONDARY  
• To explore the efficacy of bemcentinib as a single 
agent in patients with AML or MDS (Parts B1 and 
B4), in combination with low dose cytarabine in 
patients with AML (Part B2  and Part B5 ), or in 
combination with decitabine in patients with AML 
(Part B3)  
• To assess bemcentinib PK (all Part B cohorts ) 
EXPLORATORY (Parts A and B 1, B2, B3, B4 and B5 ) 
• To identify and evaluate potential predictive 
biomarkers, e.g. soluble AXL [ sAXL ] and other 
associated soluble biomarkers. Pre -treatment 
levels of biomarkers will be correlated with clinical 
endpoints  
• To establish the effects of bemcentinib on 
relevant biological endpoints in peripheral blood 
(including sAXL , peripheral blood  mononuclear 
cells [PBMC ]) and BM samples  
• To assess pharmacodynamic biomarkers in 
tissue and blood to support the clinical 
development of bemcentinib  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 17 of 131 
 • To evaluate other b iomarkers relevant to the 
investigational agents for exploratory purposes  
ENDPOINTS:  
 
 
 
 
 
 
 
 
 
  SAFETY:  
Treatment emergent adverse events ( TEAE), physical 
examination. Vital signs (i.e. blood pressure (BP) and 
heart rate (HR) , respi[INVESTIGATOR_149939] ), 
electrocardiogram (ECG), echocardiograms and 
laboratory findings including clinical chemistry, 
hematology and urinalysis.  
EFFICACY:  
AML Response criteria:  
• Objective response  (OR) or Stable Disease 
(SD) according to the revised recommendations 
of the International Working Group (IWG) in 
AML Appendix 5  [Cheson , 2003  and Döhner, 
2017 ]. SD is defined as having unchanged 
disease for at least 3 treatment cycles.  
• Proportion of patients with an OR + SD as an 
estimate of clinical benefit  
• Relapse Free Survival  
• Event Free Survival  
• Overall Survival  
• To explore the correlation between baseline 
biomarker levels and clinic al endpoints  
MDS  
Response criteria:  
• OR or SD according to the revised 
recommendations of the IWG in MDS Appendix 
6 [Cheson , 2006 ]. SD is defined as failure to 
achieve at least Partial Remission ( PR), but not 
evidence of Progressive Disease ( PD) for at 
least 3 treatment cycles.  
• Proportion of patients with an OR + SD as an 
estimate of clinical benefit  
• Relapse Free Survival  
• Event Free Survival  
• Overall Survival  
• To explore the correlation between baseline 
biomarker levels and clinical endpoints  
PHARMACOKINETIC:  
As a minimum, area  under the curve within a dosing 
interval (AUC 0-tau), maximum concentration achieved 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 18 of 131 
 (Cmax) and time to maximum concentration (T max) for 
bemcentinib will be determined from plasma. Additional 
parameters may also be reported, as deemed 
appropriate once data  are reviewed.  
PHARMACODYNAMIC  AND PREDICTIVE 
BIOMARKERS : 
The effects of bemcentinib on pharmacodynamic 
endpoints of AXL inhibition will be determined in BM 
aspi[INVESTIGATOR_787903] :  
• To identify and evaluate potential predictive 
biomarkers, e.g. sAXL and other associated 
soluble biomarkers. Pre -treatment levels of 
biomarkers will be correlated with clinical 
endpoints  
• To establish the effects of bemcentinib on 
relevant biological endpoints in peripheral blood 
(including sAXL , PBMC)  and BM samples  
• To assess pharmacodynamic biomarkers in 
tissue and blood to support the clinical 
development of bemcentinib  
• To evaluate other biomarkers relevant to the 
investigational agents for exploratory purposes  
•  Effect of bemcentinib on AXL, sAXL  and 
phospho AXL ( pAXL) and downstream effectors 
of AXL signaling, such as  Akt, pAkt, Erk, pErk, 
SLFN11, Bcl2, Puma by [CONTACT_382612] 
(e.g. flow cytometry (FCM), western blotting, 
proteomics, transcriptomics)  
• Effect of bemcentinib on gene expression by 
[CONTACT_382612] (e.g. FCM, western 
blotting, proteomics, transcripto mics, 
quantitative polymerase chain reaction ( PCR ), 
DNA -methylation analysis)  
• Effect of bemcentinib on relevant Immune cell 
populations  
• Effect of bemcentinib on the spectrum of 
mutations present within the cancer cell 
population by [CONTACT_787962]  
• To expl ore the correlation between baseline 
biomarker levels and clinical  endpoints  
STUDY DESIGN:  This Phase I b/II open -label study will run at 
approximately 20 clinical sites (in Europe  and the U nited 
States ) and may enroll up to approximately 102 
evaluable patients with AML  or MDS . Additional 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084404] 
received previous treatment with cytotoxic 
chemotherapy (with or without hematopoietic stem cell 
transplantation) or targeted or biologic agent (e.g. 
hypomethylati ng agent, tyrosine kinase inhibitor, 
antibody) and have relapsed after or have been 
refractory to treatment with such prior therapy .  
The study consists of a dose -escalation phase to 
determine the MTD of single agent bemcentinib in 
patients with relapsed or refractory AML (Part A).  
In the cohort expansion phase (Part B), bemcentinib  will 
be investigated in up to four cohorts:  
In Part A dose -escalation will continue until DLT occurs, 
at which point an MTD will be selected and used in Part 
B. The d ose of  bemcentinib  selected will be either the 
MTD or a Recommended Phase 2 dose  (RP2D) as 
agreed by [CONTACT_28749] (SMC) and 
which is supposed to be clinically effective.  
Bemcentinib will be administered orally according to a 
daily schedule, with the first two to three doses of Cycle  1 
serving as a ‘loading’ dose . Each 21 -day (three week) 
period will constitute [ADDRESS_1084405] of a 
loading dose of 200 mg administered on Days 1, 2 and 3 
followed by a daily maintenance dose of 100 mg. This 
dose may be  escalated as agreed by [CONTACT_787963] a 
maximum daily loading dose of 400 mg on Days 1, 2 and 
3 followed by a maximum daily maintenance dose of 200 
mg.  
Patients will be instructed to take bemcentinib on an 
empty stomach at a similar time each morning when th ey 
wake or more than 2 hours after a light meal with water. 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084406] 1 hour 
after taking the drug.  
Part A – Dose Escalation:  
Open label, dose -escalation study of repeat doses of 
bemcentinib as a single agent. Escalation will be 
performed according to a “3+3” design to determine the 
MTD. Between [ADDRESS_1084407] receive all loading doses and mi ss no more 
than 3 maintenance doses in Cycle 1 in order to be 
considered as informative to support dose escalation, 
unless missed doses are due to DLT.  
The decision to dose -escalate (or not) will be made by 
[CONTACT_787964] a representative from each act ively 
recruiting investigational site and a representative of the 
BerGenBio ASA study team. The decision to dose 
escalate will be based upon the tolerability of the 
bemcentinib loading dose and daily maintenance dose 
observed at the previous dose level.  
 Part B – Cohort Expansion  
The decision to proceed to Part B of the study will be 
made by [CONTACT_787965] A. Up to [ADDRESS_1084408] 
patient cohorts of up to 14 evaluable patients per cohort  
in B1, B2, B3,  B4 and up to 2 0 evaluable patients in 
cohort B5 may be explored .  
Depending upon the safety profile of bemcentinib  
observed in Part A , the initial starting dose in 
combination with cytarabine (Part B2) or decitabine (Part 
B3) may be reduced by a single dose level (i.e. MTD -1) 
which will be evaluated in at least three patients in each 
cohort before the introduction of the MTD identified in 
Part A. The bemcentinib  dose level to be investigated in 
Part B2 and Part B3 will be dependent upon the MTD 
confirmed in Part A. A dose lower than 100  mg daily is 
not available.  
Part B1 : Single agent bemcentinib in patients with AML 
who are unsuitable for intensive chemotherapy as a 
result of advanced age or co -morbidities. Patients should 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084409] one line of therapy or be 
refractory to such prior therapy .  
Part B2 : Bemcentinib will be adm inistered in 
combination with low dose cytarabine  in patients with 
AML who are unsuitable for intensive chemotherapy as 
a result of advanced age or existing co -morbidities .  
Cytarabine  will be administered subcutaneously 
according to standard practice (i.e. [ADDRESS_1084410] period of <1 month according 
to persisting myelosuppression). Cytarabine should be 
administered approximately 30 minutes after the 
bemcentinib dose .  
The bemcentinib dose to be investigated in combination 
will be confirmed by [CONTACT_4484]. If the SMC -recommended 
dose of bemcentinib is less than the single agent MTD, 
further dose escalation of bemcentinib may be 
considered until an MTD for the combination is identified, 
although the dose administered will not escalate beyond 
the single -agent MTD.  
Part B3 : Bemcentinib will be administered in 
combination with decitabine in patients with AML who are 
unsuitable for intensive chemotherapy as a result of 
advanced age or co -morbidi ties.  
Decitabine will be administered at a maximu m dose of 
20 mg/m2 body surface area by [CONTACT_5204], 
repeated daily for 5 cons ecutive days (i.e. a total of 
5 doses per 28-day treatment cycle). The total dose per 
treatment cycle must not exceed 100 mg/m2. Decitabine 
should be administered within approximately [ADDRESS_1084411] not exceed 
the MTD.  
Part B4:  Single agent bemcentinib in patients with 
previously treated MDS  (including high risk and 
intermediate  with the exception of deletion 5q  MDS) . The 
bemcentinib dose to be investigated will be confirmed by 
[CONTACT_787966] A.  
Part B5:  The Part B5 bemcentinib dose is based on the 
bemcentinib dose that was identified as safe and well 
tolerated in Part B2. Bemcentinib will be administered in 
combination with low dose cytarabine in patients with 
relapsed or refractory AML who have received at least 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084412] 3 days of treatment (loading dose) and 200  mg orally 
daily thereafter (maintenance dose).  
Cytarabine will be administered at a dose of 20  mg 
subcutaneously twice daily for 10 d ays every 28 days . 
Cytarabine should be administered approximately 30 
minutes after the bemcentinib dose.  
DOSE LIMITING TOXICITIES 
(Part A) :  DLTs will be assessed during the first 3 weeks of 
treatment with bemcentinib (Cycle 1), according to the 
National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) [NCI CTCAE] 
version 4 considered unrelated to leukemia progression 
or intercurrent illness, and defined as any of the 
following:  
• CTCAE Grade 3 or 4 nausea, vomiting, or 
diarrhea that persists despi[INVESTIGATOR_787904].  
• Any other CTCAE Grade 3 or 4 non -
hematological toxicity that is considered to be 
clinically significant and causally related to 
bemcentinib , excluding isolated changes in 
laboratory results if no clinical significance or no 
clinical sequelae and adequately improve within 
7 days.  
• Prolonged neutropenia with ANC <500 and 
platelet count <[ZIP_CODE] after Day 42 from the start 
of treatment in the absence of residual leukemia  
• Treatment discontinuation, inability to administer 
one or more bemcentinib loading dose, or 
inability to administer three bemcentinib 
maintenance doses as a result of bemcentinib -
related toxicity.  
• Any ventricular arrhythmia.  
STUDY POPULATION:  
INCLUSION CRITERIA :  1. Provision of signed written informed consent  
2. Histological , molecular,  or cytological 
confirmation of : 
AML (with the exception of AML M3)  
• Part A : Patients with relapsed or refractory 
AML following treatment with cytotoxic 
chemotherapy or a targeted or biologic  agent  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 23 of 131 
 (e.g. hypomethylating  agent, tyrosine kinase 
inhibitor, antibody)  
• Part B1 : Patients with AML who are 
unsuitable for intensive chemoth erapy as a 
result of advanced age or co -morbidities. 
Patients should have relapsed following at 
least one line of therapy or be refractory to 
such prior therapy  
• Part B2 : Patients with AML who are 
unsuitable for intensive chemotherapy as a 
result of advance d age or co -morbidities  and 
who are suitable to receive  treatment with 
cytarabine  
• Part B3 : Patients with AML who are 
unsuitable for intensive chemotherapy as a 
result of advanced age or co -morbidities and 
who are  suitable to receive treatment with 
decitabine  
• Part B4 Patients with previously treated MDS 
(with the exception of deletion 5q MDS)  
including intermediate and high risk  patients 
who must have received prior treatment for 
their disease . Prior treatment may include 
those patients who have received 
hypomethylating  agents, decitabine or other 
approved treatments for MDS.   
Or  
• Part B5:  Patients with relapsed or refractory 
AML who are unsuitable for intensive 
chemotherapy as a result of advanc ed age or 
co-morbidities meeting the following criteria:  
o Must have received at least one prior 
treatment for AML.  
o Are suitable to receive treatment with 
"low-dose" cytarabine  (LDAC). LDAC is 
defined as [ADDRESS_1084413] AML treatment  
and/or patients who have received 2 or more prior 
treatments for AML , will be restricted to 1/3 of the 
sample size (i.e. no more than 6 evaluable patients ).  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 24 of 131 
 3. Eastern Cooperative Oncology Group (ECOG) 
performance status 0, 1 or 2 [ Appendix 1 ] 
4. Age [ADDRESS_1084414] agree to practice 
highly effective methods of contraception (su ch 
as hormonal implants, combined oral 
contraceptives, injectable contraceptives, 
intrauterine device with hormone spi[INVESTIGATOR_31151],  tubal 
ligation , total sexual abstinence, vasectomy) 
throughout the study and for >[ADDRESS_1084415]-menopausal status defined as any of the 
following:  
a) Natural menopause with last menses >1 year 
ago 
b) Radiation induced oophorectomy with l ast 
menses >1 year ago  
c) Chemotherapy induced menopause with last 
menses >1 year ago  
EXCLUSION CRITERIA:  1. Patients with a matched donor who are 
candidates for allogeneic BM transplantation  
2. Pregnant or lactating  
3. History of the following cardiac conditions:  
• Congestive cardiac failure of > Class II  
severity according to the [LOCATION_001] Heart 
Association ( NYHA ) (Appendix 2 : defined as 
symptomatic at less than ordinary levels of 
activity)  
• Ischemic cardiac event including myo cardial 
infarction within [ADDRESS_1084416] dose . 
Patients with prior history or ECG evidence of 
old myocardial infarction should be discussed 
with the Sponsor to confirm eligibility.  
• Uncontrolled cardiac disease, including 
unstable angina, uncontrol led hypertension 
(i.e. sustained systolic BP >160 mmHg or 
diastolic BP >90 mmHg), or need to change 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 25 of 131 
 medication within 6 weeks of provision of 
consent due to lack of BP control  
• History or presence of sustained bradycardia 
(≤55 beats per minute ), left bundle branch 
block, cardiac pacemaker or ventricular 
arrhythmia.  
Note: Patients w ith supraventricular 
arrhythmia  should be discussed with the 
Sponsor to confirm eligibility.  
• Family history of long QTc syndrome; 
personal history of long QTc syndrome or 
previous drug -induced QTc prolongation of at 
least Grade 3 (QTc >500 ms)  
• Presence of any factors that increase the risk 
for QTc prolongation, e.g. resistant or 
inadequately treated heart failure, presence of 
hypokalemia or hypomagnesemia not 
corrected by, or not responding to, 
replacement therapy or inadequately treated 
hypothyroidism as defined by [CONTACT_516728] -
stimulating hormone not within the expected 
range of the institution.  
4. Abnormal left ventricular ejection fraction on 
echocardiography or Multi Gated Acquisition 
Scan (MUGA) (less than the lower limit of normal 
for a patient of that age at the treating institution 
or <45%, whichever is lower)  
5. Current treatment with any agent known to cause 
QT prolongation and have a risk for Torsade s de 
Pointes which cannot be discontinued at least 
five half -lives or two weeks prior to the first dose 
of study treatment . Please see Appendix [ADDRESS_1084417] 
of relevant medications  
6. Screening 12 -lead ECG with a measurable QTc 
interval according to Fridericia’s correction 
>[ADDRESS_1084418] been afebrile for 48 hours following 
the initiation of antimicrobials are eligible  
8. Inadequate liver function as demonstrated by 
[CONTACT_7406] ≥1.5 times the upper limits of 
normal range (ULN) or alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) ≥2.[ADDRESS_1084419] (or ≥[ADDRESS_1084420] for ALT or 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084421] in the presence of liver involv ement by 
[CONTACT_787967])  
9. Inability to tolerate oral medication s 
10. Existing gastrointestinal disease affecting drug 
absorption such as celiac disease or Crohn ’s 
disease  
11. Known lactose intolerance  
12. Requires vitamin K antagonists. Note: Patients 
receiving low doses prescribed to maintain the 
patency of venous access devices may be 
included  
13. Treatment with any of the following; histamine 
receptor [ADDRESS_1084422] disease  
17. Hematopo ietic ste m cell transplantation within 
6 months  
18. Impaired renal function as  demonstrated by a 
creatinine clearance of <30 mL/min determined 
by [CONTACT_3158] -Gault formula  
19. Radiotherap y or chemotherapy within the 
[ADDRESS_1084423] dose of bemcentinib 
being administered (other than hydroxyurea)  
20. Receiving an investigational anti -cancer 
treatment concurrently or within 14 days or five 
half-lives (whichever is shorter) of either the 
parent drug or any known active metabolite prior 
to the start of bemcenti nib 
21. Unresolved CTCAE >Grade 2 toxicity (other than 
stable toxicity) from previous anti -cancer therapy 
excluding alopecia  
22. Any evidence of severe or uncontrolled systemic 
conditions (e.g., severe hepatic impairment) or 
current unstable or uncompensated respi [INVESTIGATOR_787905]003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 27 of 131 
 for the patient to participate in the study or which 
could jeopardize compliance with the protocol  
23. Known active, uncontrolled central nervous 
system (CNS) disease including CNS leukemia  
24. Known active i nfection with human 
immunodeficiency virus (HIV), hepatitis B or C 
viruses – screening for viral infections is not 
required for entry to this study  
25. Major surgery within 28 days prior to the start of 
bemcentinib – excluding skin biopsies and 
procedures for insertion of central venous access 
devices  
26. Hypersensitivity to cytarabine, decitabine or any 
of their excipi[INVESTIGATOR_840]  
27. Prior exposure to Astellas ASP2215  (FLT3/AXL 
inhibitor -Gilteritinib ) 
TREATMENT AND 
INTERVENTIONS : Patient eligibility for the study will be determined within 
[ADDRESS_1084424] dose of bemcentinib . Screening 
assessments will be conducted according to the 
Schedule of Events ( Tables 4-6) in Section 11. 
Eligible patients will visit the study site to receive study 
treatment and protocol -specified procedures according 
to the relevant Schedule of Events ( Tables 4-6) in 
Section 11 . 
In order to reduce the risk of tumor lysis syndrome all 
patients will be asked to drink up to two lit ers of fluid in 
the 24 -hour period prior to starting treatment with 
bemcentinib and on Day 0, Day 1, Day 2 and Day 3. All 
patients will receive treatment with allopurinol  (or 
equivalent) for at least the first week of treatment or until 
their serum uric acid is within the normal range or 
considered as not clinically significant. If a patient has a 
pre-existing  condition where uric acid lev els are higher 
(i.e. gout) pre -bemcentinib  uric acid levels may be 
considered as normal).  
The treatment period will consist of continuous 21 -day 
treatment cycles. Patients will be intensively monitored 
throughout Day 1 to Day 4 inclusive of Cycle 1, and i n 
addition will attend the clinic on Day 8, and  Day 15. 
Patients will attend the clinic once a week during Cycle 2 
(Day 1, 8 and 15) and then once per cycle thereafter.  
The study period will consist of screening, treatment, 
Final Study Visit, and follow -up. The Final Study Visit will 
occur 28 days after the patient has discontinued study 
treatment.  The patients will be followed by [CONTACT_787968]003 v 10.0 (US);  
[ADDRESS_1084425] with fami ly members 
or community health care providers (family practitioner, 
nurse or family liaison/social worker), or public health 
records (where applicable). Every effort should be made 
to establish the patient’s survival status at 3 -monthly 
intervals, or less.  
BEMCENTINIB : 
FORMULATION/DOSE/ROUTE 
OF ADMINISTRATION:  Bemcentinib is presented for oral dosing in capsules 
each containing [ADDRESS_1084426] 
three  doses may comprise of a ‘loading’ dose.  
Part A : Dose is ascending per dose cohort. The starting 
dose of bemcentinib (Cohort 1) will be 200 mg on Cycle 
1, Days 1, 2 and 3 (loading dose), followed by a daily 
maintenance dose of 100 mg. This dose may be 
escalated as agreed by [CONTACT_787963] a maximum daily 
loading dose of 400 mg on Days 1, 2 and 3 followed by 
a maximum daily maintenance dose of 200 mg.  
Please refer to Section [IP_ADDRESS]  for more details on dose 
escalation rules.  
Part B:  Bemcentinib will be administered at the MTD or 
RP2D in Part B1 and Part B4  
In Part s B2 and B3 bemcentinib will be administered at a 
dose identified by [CONTACT_4484] , which may be lower than the 
bemcentinib dose confirmed in Part A.  Depending upon 
the safety profile of bemcentinib observed in Part A the 
initial starting dose in combination with cytarabine  or 
decitabine may be reduced by a single dose level ( e.g., 
MTD -1) which will be evaluated in at least [ADDRESS_1084427] 3 days of treatment (loading dose) and 
200 mg orally daily thereafter (maintenance dose).  
DURATION AND FREQUENCY  Patients may continue to receive 
bemcentinib  for as long as, in the opi[INVESTIGATOR_8574], they continue to derive 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084428] be discontinued . 
However, patients experiencing disease 
progression may be  permitted to continue 
treatment with bemcentinib, where the 
investigator believes patients may 
continue to derive some clinical benefit 
from continued treatment.  
Clinical benefit in this context is defined as meeting one 
or several of the following criteria: evidence of disease 
stabili zation after documented initial progression (patient 
is stably worse), tolerance of drug(s), absence of rapid 
progression based on peripheral  or bone marrow blasts 
and clinical hematology and clinical chemistry 
parameters, maintenance of good performance status 
(PS of 2 or less and not deteriorating], absence of 
worsening clinical symptoms (i.e., no symptomatic 
deterioration ) and/or improvement s in patient’s quality of 
life). 
The decision to continue treatment must be discussed 
and agreed between the treating investigator, the patient 
and the Sponsor. All decisions will be documented in 
writing. Patients dosed beyond progression will continue 
to be evaluated for potential clinical benefit and safety.  
This will not affect the time point of disease progression 
from the perspective of trial analysis.  
Patients who permanently discontinue treatment with 
one of the combination agen ts in Part s B2, B3 and B5 
may continue to receive the other study drug alone  if it is 
safe to do so ( at investigator discretion) in the absence 
of disease progression or intolerable toxicity. The 
investigator may also decide to discontinue both study 
treatments at this time .  
EVALUATION:  
  As outlined in the relevant Schedule of Events 
(Tables  6-8). 
Safety:  
Physical examination  
Vital signs  
ECG  
Echocardiogram  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 30 of 131 
 Routine blood panel (hematology, clinical chemistry and 
coagulation panel)  
Adverse events (AEs) (CTCAE)  
Efficacy:  
Peripheral blood count; BM aspi[INVESTIGATOR_787906] s: 
Bemcentinib PK parameters in plasma  (Part A and Part 
B) 
Pharmacodynamic s: 
The effects of bemcentinib on pharmacodynamic 
endpoints, gene expression and genomics in BM 
aspi[INVESTIGATOR_787907] .  
FOLLOW UP : AEs will be monitored for [ADDRESS_1084429] 
resolved  to <Grade 1 or less , stabili zed or returned to 
baseline. Follow up monitoring for AEs may be 
conducted over the telep hone.  Serious adverse events 
(SAEs ) with a suspected relationship to bemcentinib will 
be collected indefinitely.  
The study will be completed when all patients have 
completed their final study visit.  
All patients will be followed for survival after they have 
permanently disconti nued from study treatment at 
≤[ADDRESS_1084430] be collected in the 
electronic case report form ( eCRF ). 
The study will be completed when all patients have an 
OS eve nt, unless the Sponsor terminates OS follow -up 
once all patients have discontinued study treatment . 
STATISTICAL METHODS  As this is an early study of bemcentinib only descriptive  
analysis will be performed on safety dat a. Preliminary  
statistical analysis will be performed on objective 
response rates in Part B.   
Safety :  
All safety and tolerability assessments will be based on 
the safety analysis set (all patients who have received at 
least one dose of study medication) .  
Efficacy : 
Efficacy assessments will be based on the safety 
analysis set.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 31 of 131 
 Note: patients treated with bemcentinib beyond disease 
progression will be followed for the same safety and 
efficacy assessments as for all other patients enrolled 
into the study unti l they are withdrawn from the study. 
The data for patients treated beyond progression will be 
presented in both a combined output (with all patients) 
and also a separate output (to reflect a new period of 
analysis). All data collected will be included in t he study 
CSR.  
Pharmacokinetics : 
Individual and mean bemcentinib plasma concentration -
time data will be presented in tabular and graphical form . 
PK parameters for bemcentinib will be derived from an 
appropriate PK model w ill be determined using a 
non-compartmental analysis . Full details of the PK 
analysis will be presented in a PK Analysis Plan.  
Pharmacodynamics : 
Pharmacodynamic data will be listed and summarized by 
[CONTACT_787969].  
 
  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 32 of 131 
 7. Introduction  
This study is a dose -escalation of bemcentinib , an AXL kinase inhibitor , in patients with acute 
myeloid leukemia (AML) , followed by a cohort expansion study of bemcentinib either as a 
single agent  in patients with AML or MDS,  or in combination with cytarabine ( cytosine 
arabinoside , Ara-C) or decitabine in patients with AML .  
7.1. Pre-clinical Studies with Bemcentinib  
7.1.1.  Summary of Pre -clinical Activity  
Bemcentinib demonstrates  potent inhibition of AXL in biochemical and cell-based kinase 
inhibition assays . The selectivity of bemcentinib for AXL is illustrated in Table 1. 
Table 1: Bemcentinib Kinase Selectivity Profile  
Kinase  Kinome Scan  
binding assay  
(Kd) KinaseProfiler  
kinase activity assay  
(IC50) BaF3 cell -based kinase 
activity assay  
(IC50) 
nM fold nM fold nM fold 
AXL 0.4 1 4.6 1 63 1 
Tie2 270 680 30 6.4 355 5.5 
Ret 73 180 38 8.1 >316  >5 
Flt1 400 >1000  40 8.7 >1000  >15 
Flt4 460 >1000  41 8.8 >1000  >15 
Yes 810 >1000  43 9.2 n/a n/a 
n/a = not applicable  
Bemcentinib  inhibits the growth and survival of tumor cell lines derived from a range of solid 
and leukemic tumors. In vitro  activity of bemcentinib has been examined in a range of different 
AML cell lines where exposure -induced  differentiation  and arrest in the G1 p hase of the cell 
cycle  was accompanied by a r eduction in levels of phosphorylated AXL and phosphorylated 
ERK. Early in vitro  and ex vivo  studies indicate that AXL inhibition with bemcentinib also 
inhibits proliferation of clonal cells derived from patients with MDS.  
The in vivo  efficacy of bemcentinib has been evaluated in two different murine models of AML. 
Studies in the MDV4 -11 xenograft  model  showed a dose -dependent reduction in tumor burden 
following oral treatment with bemcentinib . A dose -depe ndent reduction in both AXL and ERK 
phosphorylation levels were noted . Bemcentinib treatment also significantly inhibited tumor 
growth in the OCI -AML5 xenograft model. Furthermore,  bemcentinib has been shown to 
significantly prolong survival in the syngeneic bone marrow  (BM)  transplantation Hoxa9/Meis1 
mouse model [Ben-Batalla, 2013 ]. 
As described by [CONTACT_787970] -Batalla, BM cells from 7 out of 11 patients with  primary AML were 
sensitive to bemcentinib (IC 50 = 1.9  0.5µM), and this inhibition was independent of FLT3 
status since FLT3 WT AML cells were similarly sensitive to bemcentinib (n=3/8; p=0.4212). 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 33 of 131 
 Furthermore, the EC 50 of response to bemcentinib correlated with AXL protein expression 
levels (n=10; R2=0.84; p< 0.05), with AXL negative cells being almost completely resistant to 
bemcentinib . Bemcentinib treatment also significantly sensitized BM cells from primary patient 
AML cells to cytarabine  [Ben-Batalla, 2013 ].  
Population studies have identified both AXL expression and circulating levels of Gas 6 as 
independent predictors of prognosis  [Whitman, 2013 ].  
A modest substrate and time -dependent inhibition of CYP3A4/5 activity by [CONTACT_787971] . Preliminary results from a 
cytarabine  in vitro metabolism study indicate that cytarabine  does not undergo ex tensive 
metabolism by [CONTACT_097]3A4. Consequently,  it is considered unlikely that there will be an interaction 
between bemcentinib and cytarabine . Decitabine does not undergo CYP450 mediated 
metabolism; therefore, there is no rationale for the evaluation of its i nteraction with 
bemcentinib . 
A comprehensive summary of the pre -clinical activity of bemcentinib is presented in the current 
version of the Investigator’s Brochure (IB).  
7.1.2.  Summary of Pre -clinical Toxicology  
To support clinical studies  with bemcentinib a series of animal toxicology and safety studies, 
including 28 -day repeat dosing studies in rodents and monkeys and a single dose telemetered 
cardiovascular (CV) safety study in monkeys, have been conducted. Comparisons of the data 
reported in the rodent and monkey studies indicate that primates are more sensitive to 
bemcentinib on a per body weight basis.  
The results of the repeat dose 28 -day study in monkeys identified the liver, reticuloendothelial 
system and hematopoietic  system as target or gans. These events were largely thought to be 
due to macrophage accumulation, consistent with phospholipi[INVESTIGATOR_16215], and were only partially 
reversible across the planned 16-day recovery period, although this was anticipated to be due 
to the slow elimination of  the compound. Similar findings were identified in mice treated across 
a range of dose levels with partial recovery noted 16 days later.  
In the CV safety study, single oral administration of bemcentinib (7.5 mg/kg – 60 mg/kg) was 
associated with recoverabl e, non -adverse decreases in heart rate and corresponding 
increases in the RR interval durations. Dose -dependent increase in QTc interval was noted at 
all dose levels; the magnitude of the QTc effect at the highest dose level was 17%, whilst at 
7.5 mg/kg an d 15 mg/kg, the change generally fell below 10% compared to vehicle control 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 34 of 131 
 and pre -dose values. These observations were consistent with the previously identified IC 50 
for human ether -à-go-go related gene (hERG ) channel inhibition of 0.53  M bemcentinib . 
Bemcentinib was negative in the Ames bacterial mutation assay, suggesting that bemcentinib 
is not mutagenic. Bemcentinib was also negative in an in vitro  mammalian cell cytogenetic 
study in human lymphocytes suggesting that bemcentinib is not clastogenic.  
7.1.3.  High Dose Steroids and Mouse Model  
In an academic model of osteoporosis, bemcentinib was administered in combination with 
high dose corticosteroids (12.5 mg/kg per day of prednisolone). In this research study, [ADDRESS_1084431] is curre ntly under investigation. The mice received very high levels 
of corticosteroids to i nduce rapid onset of osteoporosis – on a mg/kg basis, the corticosteroid 
dose was 20 -fold higher than a typi[INVESTIGATOR_144252]. 
Additionally, the dose of bemcentinib used in this model was 50  mg/kg which is 6 -fold higher 
than the maximum exposure observed in human clinical studies.  
In a follow -up study, the equivalent dose of prednisolone (0.208  mg/kg) was given as an oral 
bolus once a day for 9 days. The prednisolone dosed orally was well tolerated and no major  
issues were reported upon necropsy (336 -TR-324-TOX). It was concluded that the toxicity 
observed when the prednisolone was continually administered by [CONTACT_787972], 
was a direct consequence of sustained exposure to steroid which would not occ ur when it is 
dosed orally once a day.  
Please refer to the current version of the IB for further information on the results of the 
preclinical studies when bemcentinib was combined with steroids.  
7.2. Clinical Studies with Bemcentinib  
There has been one previou s clinical study completed with bemcentinib (Protocol BGBC001 ). 
This study explored the effect of a single dose of bemcentinib (dose range: 50, 100, 150, 200, 
400, 600, 1000 and 1500 mg) in healthy male volunteers  under fasted conditions, with a sub -
study in limited number of the volunteers to assess dosing under fed conditions . Eight dose 
levels (50 mg, 100 mg, 150 mg, 200 mg, 400 mg, 600 mg, 1000 mg and 1500 mg) were 
administered under fasted conditions to  cohort s of four subjects  (32 subjects  in total ). Seven 
of these subjects we nt on to receive  the same dose of bemcentinib administered under fed 
conditions . Other studies with bemcentinib are being conducted in triple negative breast 
cancer or triple negative inflammatory breast cancer, Stage IIIb or Stage IV non -small cell lung 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 35 of 131 
 cancer (NSCLC), advanced adenocarcinoma of the lung and melanoma (please refer to the 
current version of the bemc entinib  IB or clinicaltrials.gov for further details).  
7.2.1.  Summary of Clinical Safety  
Please refer to the current version of the bemcentinib IB for the most up -to-date safety 
information.  
In general exposure to bemcentinib in BGBC001  bemcentinib was well tolerated with all 
toxicities being spontaneously reversible and predominantly gastrointestinal in nature . No 
serious adverse events (SAE) were reported. Reported adverse events  (AE) are summarized  
in Table 2.  
Table 2: Bemcentinib -Related Adverse Events Reported Following a Single Oral 
Administration of Bemcentinib (50 mg to 1500 mg) to Healthy Male Subjects  
Dose 
(mg)  Number of Subjects  Toxicity  Maximum Grade  
(CTCAE version 4.0)  
50 4 fasted; [ADDRESS_1084432] Pain  One 
100 4 fasted; 2 fed  Paraesthesia  
Orthostatic hypotension  One 
150 4 fasted; 1 fed  Abdominal Distension (n=2) One 
200 4 fasted; [ADDRESS_1084433] infection  One 
400 4 fasted; 2 fed  Diarrhoea  One 
600 4 fasted  Diarrhoea  
Flatulence  
Nausea (n=2)  One 
One 
One 
1000  4 fasted  Nausea  One 
1500  4 fasted  Diarrhoea  
Nausea  
Vomiting  
Headache  
Dizziness  
Oropharyngeal pain  One 
Two 
Two 
One 
One 
One 
 
 
[IP_ADDRESS].  ECG Findings  
In light of the findings reported in the safety pharmacology studies described in Section 7.1.2, 
all subjects in study BGBC001 underwent serial ECG recordings following the administration 
of bemcentinib . The overall pattern indi cated that bemcentinib administration was 
accompanied by a variable increase in QTc interval according to Fridericia’s correction 
(QTcF ), the magnitude of which was related to systemic exposure. The maximum QTcF 
recorded was Grade 1 in severity.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 36 of 131 
 7.2.2.  Summary o f Clinical Pharmacokinetics  
Concentrations of bemcentinib were quantified in plasma samples from subjects enrolled in 
Study BGBC001 using a fully validated liquid chromatography/tandem mass spectrometry 
(LC/MS/MS) method with a lower limit of quantificatio n of 2.0 ng/mL. Pharmacokinetic ( PK) 
parameters were derived by [CONTACT_105] -compartmental analysis using WinNonlin Phoenix Version 
6.3 (Pharsight Corporation Inc., Mountain View, CA, [LOCATION_003], 2012) . 
Following a single oral dose of bemcentinib at doses between 50  mg and 1500 mg , 
administered under fasted conditions , mean maximal plasma concentrations of 7.63 ng/mL to 
388 ng/mL were reached at 8 hours (h)  to [ADDRESS_1084434] -dose  as presented in Figure 1.  
Figure 1: Mean Plasma Concentrations of Bemcentinib Following a Single Oral 
Administration of Bemcentinib at 50, 100, 150, 200, 400, 600, 1000 and 1500 mg to 
Healthy Male Subjects  
 
 
 
The mean apparent terminal half-life (t 1/2) of bemcentinib was 45.[ADDRESS_1084435] variability in systemic exposure ( area under the curve from time zero to infinity 
(AUC 0-∞) and  maximum  concentration achieved  (Cmax)) to bemcentinib at 50 mg to 1500 mg 
was generally high ( coefficient of variation of 25.8% to 96.7% for area under the concentration -
[PHONE_3197]
0 12 24 36 48 60 72 84 96 108 120Concentration (ng/mL)
Time (h)50 mg 100 mg 150 mg 200 mg
400 mg 600 mg 1000 mg 1500 mg
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 37 of 131 
 time curve ( AUC 0-t) and  Cmax), most probably reflecting variable absorption. Across this dose 
range C max of bemcentinib increased approximately dose proportionately , although the AUC 0-
∞ of bemcentinib increased slightly greater than dose proportionately.  
Following administration of bemcentinib with food (whole milk and buttered toast) to [ADDRESS_1084436] fasted. This study, BGBC003, will evaluate both Formulation 1 (taken when patients are 
fed), and Formulation 2 (taken when patients are fasted). Please see Section [IP_ADDRESS]  and the 
current version of the bemcentinib  IB for more details . 
In Study BGBC001, 32 subjects received doses of bemcentinib in the range 50 to 1500 mg 
under fasted conditions, of which seven also received the same dose of bemcentinib under 
fed conditions . The time to maximum concent ration ( tmax) and the apparent t ½ were generally 
comparable between fed and fasted conditions; t max ranged from 6 to 30 hours and t ½ ranged 
from 30.2 to 77.2 hours (except in one subject where t ½ was reliably estimated as 165 hours). 
There was an increase in systemic exposure to bemcentinib in three subjects, no appreciable 
change in three subjects and an apparent reduction in systemic exposure in one subject when 
bemcentinib was given with food co mpared to under fasted conditions.  
Overall, C max and area under the curve from time zero to 48 hours ( AUC 0-48h) under fed 
conditions were 29% and 21% greater, respectively compared to fasted conditions; however, 
the 95% confidence interval ( CI) of the rati o (fed/fasted) included 100%, indicating that the 
apparent effect of food was not statistically significant. The elimination of bemcentinib was 
slow with a t ½ of longer than 24 hours. A consequence of this prolonged t ½ is the delay in the 
time taken to ach ieve steady state, which is estimated to be approximately two weeks following 
the initiation of bemcentinib administration. Such a delay would not be therapeutically 
acceptable in patients with advanced cancers.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 38 of 131 
 The proposed starting dose and dosing schedu le for clinical studies of bemcentinib in patients 
was therefore based on a one -compartment model, incorporated a lag time and no weighting 
to available clinical PK data. According to this model it was anticipated that the application of 
a loading dose (on  Days 1 and 2) would enable a rapid achievement of therapeutic levels of 
bemcentinib , with a maintenance daily dosing from Day [ADDRESS_1084437] preventing wide changes in systemic concentration during therapy (see Figure 2 and 
Figure 3). 
Current PK data suggest that bemcentinib would be best administered as a loading  dose on 
up to the first three days of treatment, followed by a daily maintenance dose (see  Figure 2 and 
Figure 3).  
Figure 2: Simulated Plasma Concentrations of Bemcentinib for 600 mg Loading Dose 
on Days 1 and 2 and Daily Dose of 200 mg from Day 3 (fed)  
 
 
050100150200250300350400450
0 24 48 72 96 120 144 168 192 216 240 264Concentration (ng/mL)
Time (h)
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 39 of 131 
 Figure 3: Simulated Plasma Concentrations of Bemcentinib for 600 mg Loading Dose 
on Days 1 and 2 and Daily Dose of 200 mg from Day 3 (fasted)  
 
AE data to date suggest that gastrointestinal toxicities are more pronounced during and shortly 
after administration of the bemcentinib loading dose. It remains desirable to achieve 
bemcentinib stead y-state as soon as possible in patients with advanced can cer, and in order 
to improve compliance during initial bemcentinib dosing, a [ADDRESS_1084438] ensuring steady -state is still reached by [CONTACT_2006] 4 (see Figure 4). 
Figure 4: Predicted Plasma Concentrations of Bemcentinib after 1200 mg Loading Dose 
Given as 600 mg on Days 1 and 2 or 400 mg on Days 1, 2 and 3, followed by [CONTACT_787973] 200 mg (fasted)  
 
 

   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084439] of a loading dose of 200 mg administered on Days  1, 
2 and 3 followed by a daily mai ntenance dose of 100 mg. This dose may be escalated as 
agreed by [CONTACT_787963] a maximum daily loading dose of 400  mg on Days 1, 2 and 3 followed 
by a maximum daily maintenance dose of 200 mg . A Recommended Phase 2 dose ( RP2D ) 
will be selected in Part A for f urther evaluation in Part B.  
[IP_ADDRESS].  Formulation [ADDRESS_1084440] that bemcentinib exhibits increased solubility in an acid environment, thus 
patient s should receive Formulation 2 in the fasted state upon waking and should not be 
receiving baseline gastric protectants including Proton Pump Inhibitors, Histamine Receptor 
two antagonists or antacids when starting therapy with bemcentinib . They may receiv e 
treatment with these agents in the evening if required for symptoms; but only when established 
on bemcentinib therapy  (i.e. following at least one week of  treatment with bemcentinib ).  
The increased absorption of bemcentinib seen with Formulation [ADDRESS_1084441] dossier (IMPD) . 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 41 of 131 
 8. Study Objectives and Endpoints  
8.1. Objectives  
8.1.1.  Primary Objectives  
Part A  
To identify the maximum tolerated dose (MTD) of bemcentinib in AML patients who have 
received previous treatment with cytotoxic chemotherapy (with or without hematopoietic  stem 
cell transplantation) or a targeted or biologic agent (e.g. hypomethylating agent, tyrosine 
kinase inhibitor, antibody) , and have relapsed after or have been refractory to treatment with 
such prior therapy . 
Part B  
To identify the safety and tolerability of bemcentinib as a single agent in patients with AML or 
MDS (Parts B1 and B4 ), or in combination with low dose cytarabine  (Part B2  and Part B5 ) or 
decitabine (Part B3) , in patients with AML who are unsuitable for intensive chemotherapy  as 
a result of advanced age or existing co -morbidities.  
8.1.2.  Secondary Objectives  
Part A  
• To identify the Dose Limiting Toxicity (DLT)  profile of bemcentinib  
• To explore the safety and efficacy of bemcentinib  
• To characteri ze the PK profile of bemcentinib  
Part B  
• To explore the efficacy of bemcentinib , as a single agent in patients with AML or MDS 
(Parts B1 and B4)  
• To explore the efficacy of bemcentinib  in combination with low dose cytarabine  
(Part B2 and Part B5 ) or decitabine (Part B3), in patients with AML who are unsuitable 
for intensive chemotherapy  
• To evaluate bemcentinib PK (all Part B  cohorts ) 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 42 of 131 
 8.1.3.  Exploratory Objectives  
Parts A and B  
• To identify and evaluate potential predictive biomarkers, e.g. soluble AXL (sAXL ) and 
other associated soluble biomarkers. Pre -treatment levels of biomarkers will be 
correlated with clinical endpoints  
• To establish the effects of bemcentinib  on relevant biological endpoints in peripheral 
blood (including sAXL peripheral blood mononuclear cells [PBMC ]) and BM samples  
• To assess pharmacodynamic biomarkers in tissue and blood to support the clinical 
developm ent of bemcentinib  
• To evaluate other biomarkers relevant to the investigational agents for exploratory 
purposes  
8.2. Endpoints  
8.2.1.  Safety Endpoints  
Safety and tolerability will be assessed by [CONTACT_787974]-defined time -points du ring the study:  
• Treatment emergent AEs 
• Physical examination  
• Vital signs including blood pressure (BP), heart rate (HR) , respi[INVESTIGATOR_427671]  
• Electrocardiogram (ECG)  
• Echocardiogram  
• Laboratory findings including clinical chemistry, hematology and urinalysis  
8.2.2.  Efficacy Endpoints  
In AML, e fficacy endpoints will be measured  using the following response criteria . 
• Objective Response (OR) or Stable Disease (SD) according to the revised  
recommendations of the International Working Group (IWG) in AML [Cheson , 2003  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 43 of 131 
 and Döhner, 2017 ] (see Appendix 5 ). SD is defined as having unchanged disease for 
at least 3 treatment cycles.  
• Proportion of patients with an OR + SD as an estimate of clinical benefit.  
• Relapse Free Survival  
• Event Free Survival  
• Overall Survival  
• To explore the correlation between baseline biomarker levels and clinical endpoints  
In MDS, efficacy endpoints will be measured using the following response criteria.  
• OR or SD according to the revised recommendations of the IWG in MDS (see 
Appendix  6). SD is defined as failure to achieve at least PR but not evidence of PD for 
at least 3 treatment cycles.  
• Proportion of patients with an OR + SD as an estimate of clinical benefit.  
• Relapse Free Survival  
• Event Free Survival  
• Overall Survival  
• To explore the correlation between baseline biomarker levels and clinical endpoints  
8.2.3.  Pharmacokinetic Endpoints  
As a minimum, area under the curve  within a dosing inter val (AUC 0-tau), C max, and time to 
maximum concentration (T max) for bemcentinib will be determined from plasma. Additional 
parameters may also be reported, as deemed appropriate once data are reviewed.  
8.2.4.  Pharmacodynamic and Predictive Endpoints  
The effects of bemcentinib on pharmacodynamic endpoints of AXL inhibition will be 
determined in BM aspi[INVESTIGATOR_787908] :  
• To identify and evaluate potential predictive biomarkers, e.g. sAXL and other 
associated soluble biomarkers. Pre -treatment levels of biomarkers will be 
correlated with clinical endpoints  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 44 of 131 
 • To establish the effects of bemcentinib  on relevant biological endpoints in 
peripheral blood (including sAXL PMBC s) and BM samples  
• To assess pharmacodynamic biomarkers in tissue and blood to support the clinical 
development of bemcentinib  
• To evaluate other biomarkers relevant to the investigational agents for exploratory 
purposes  
• Effect of bemcentinib on AXL, sAXL  and phospho AXL ( pAXL) and downstream 
effectors of AXL signaling, such as  Akt, pAkt, Erk, pErk, SLFN11 , Bcl2, Puma by 
[CONTACT_382612] (e.g. flow cytometry ( FCM ), western blotting, proteomics, 
transcriptomics)  
• Effect of bemcentinib on gene expression by [CONTACT_382612] (e.g. FCM, 
western blotting, proteomics, transcriptomics, quantitative polymerase chain 
reaction ( PCR ), DNA -methylation analysis)  
• Effect of bemcentinib on relevant immune cell populations  
• Effect of bemcentinib on the spectrum of mutations present within the cancer cell 
population by [CONTACT_787962]  
• To explore the correlation between baseline biomarker levels and clinical 
endpoints  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 45 of 131 
 9. Study Design  
9.1. Overview  
This is a Phase Ib/II, open -label, dose -escalation and cohort expansion study to obtain a 
preliminary assessment of the safety, tolerability and efficacy of bemcentinib , a small molecule 
inhibitor of AXL kinase in patients with AML  or MDS . The study will be conducted  at up to 
approximately 20 sites in Europe  and the US and will be performed in approximately 102 
evaluable patients with AML or MDS . Additional countries and sites may be added as required 
to meet the enrolment needs of the study.  
In Part A bemcentinib will be admin istered  as monotherapy in patient s with relapsed or 
refractory AML following previous treatment with cytotoxic chemotherapy (with or without 
hematopoietic  stem cell transplantation) or a targeted or biologic agent (e.g. hypomethylating 
agent, tyrosine  kinase inhibitor, antibody) . 
In Part B bemcentinib will be administered  as a single agent in patients with AML who are 
unsuitable for intensive chemotherapy  (i.e. cytarabine /anthracycline on a 3+7 dose or 
equivalent) as a result of advanced age and/or existing co -morbidities (Part B1)  or in MDS 
patients who have previously received treatment (Part B4)  and a further 3 cohorts of 
bemcentinib administered in combination with low dose cytarabine (Part B2  and Part B5 ) or 
decitabine (Part B3) in patien ts with AML who are unsuitable for intensive chemotherapy 
because of advanced age or existing co -morbidities will be investigated  
In all parts of the study , AML  patients with a matched donor and who are candidates for 
allogeneic BM transplantation are not eligible to participate .  
Bemcentinib will be administered orally according to a daily schedule during  continuous 
21-day treatment cycles . During Cycle 1, Week [ADDRESS_1084442] 3 doses of bemcentinib may 
serve as a  ‘loading’ dose .  
Dosing will consist of a loading dose of [ADDRESS_1084443] 
1 hour after taking the drug.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 46 of 131 
 In Part A  the study will follow a 3+3 design to explore the safety and tolerability of repeat  
dosing of bemcentinib , and to identify the MTD . A minimum of 6-10 patients will be treated at 
the MTD  or RP2D, as determined by [CONTACT_4484] . Depending upon the results of this phase of 
the study , the safety and efficacy of bemcentinib may be established in up to 4 disease -specific 
cohorts in Part B .  
Part B 1 
Single agent bemcentinib will be administered to patients with AML who are unsuitable for  
intensive chemotherapy (i.e. cytarabine /anthracycline on a 3+7 dose or equivalent) as a result 
of advanced age and/or existing co -morbidities . In order to be eligible patients should have 
received at least one line of previous therapy .  
Part B2  
Bemcentinib will be administered in combination with low dose cytarabine  in patients with AML 
who are unsuitable for intensive chemotherapy as a result of advanced age or existing 
co-morbidities .  
Part B3  
Bemcentinib will be administered in combination with decitabine in patients with AML  who are 
unsuitable for intensive chemotherapy as a result of advanced age or existing co -morbidities.  
Part B4  
Single agent bemcentinib will be administered to patients with previously treated MDS  
(including high risk and intermediate with the exception of deletion 5q MDS ). 
Part B5  
Bemcentinib will be administered in combination with cytarabine in patients with AML who are 
unsuitable for intensive chemotherapy as a result of advanced age or existing co -morbidities. 
Patients must have received at least one prior treatment for AML.  
Please refer to Figure 5 for an outline of the overall study design.  
  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 47 of 131 
 Figure 5: BGBC003 Study Design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.2. Study Specifics  
9.2.1.  Phase I DLT Assessment Period  
During the dose -escalation phase  (Part A) , safety, tolerability, PK, and preliminary clinical 
activity of bemcentinib will be assessed , and the MTD established,  in patients who have 
received previous treatment with cytotoxic chemotherapy or a targeted or biologic agent (e.g. 
hypomethylating agent , tyrosine kinase inhibitor, antibody)  and have relapsed after or have 
been refractory to treatment with such prior therapy . Patients receiving an allograft in first 
remission would be eligible at the time of relapse.  
A loading dose (Cohort 1) of 200 mg administered on Cycle 1, Days 1, 2 and 3 followed by a 
daily maintenance dose of 100 mg during continuous 21-day treatment cycle s will be  
evaluated . This dose may be escalated as agreed by [CONTACT_787963] a maximum daily loading 
dose of 400 mg on Days 1, 2 and 3 followed by a maximu m daily maintenance dose of 200  mg 
(see Section [IP_ADDRESS]). At least 3 evaluable patients will be entered per cohort .  
Part A  
Enrolment 3+3 dose escalation  
3-6 patients per cohort to receive daily doses of bemcentinib  (21day cycle)  
Safety, tolerability, PK efficacy assessed in relapsed/refractory (R/R) AML  
Dose allocation  
Part B5  
Bemcentinib  + low 
dose cytarabine  
N ≤2 0 
Safety, tolerability, 
PK, efficacy  
AML Unsuitable for 
Intensive 
Chemotherapy  
Part B4  
Single Agent  
bemcentinib  
N ≤ 14  
Safety, tolerability, 
PK, efficacy  
Previously treated 
MDS  
Part B3  
Bemcentinib  + 
decitabine  
N ≤ 14  
Safety, tolerability, 
PK, efficacy  
AML Unsuitable for 
Intensive  
Chemotherapy  
Part B2  
Bemcentinib  + low 
dose cytarabine  
N ≤ 14  
Safety, tolerability, 
PK, efficacy  
AML Unsuitable for 
Intensive 
Chemotherapy  
Part B1  
Single Agent  
bemcentinib  
N ≤ 14 
Safety, tolerability, 
PK, efficacy  
R/R AML  
Unsuitable for 
Intensive 
Chemotherapy  
Assess 6 -10 patients with R/R AML with proposed RP2D  
Ongoing Safety Review  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 48 of 131 
 [IP_ADDRESS].  Dose Escalation Scheme  
Initially three patients will be recruited into Cohort [ADDRESS_1084444] receive  all loading doses and 
miss no more than 3 maintenance doses in Cycle 1 in order to be consid ered as informative 
to support dose escalation , unless the missed doses are due to bemcentinib toxicity (see 
Section [IP_ADDRESS] . Dose Limiting Toxicity).  
The decision to dose -escalate (or not) will be made by [CONTACT_787964] a representative 
from each active ly recruiting  investigational site and  a representative of the  BerGenBio AS A 
study team . Minutes of the SMC  meeting will be recorded and circulated for final approval 
before being placed in the Trial Master File (TMF) . The decision to dose escalate will be based 
upon the tolerability of bemcentinib . 
Where dose escalation occurs, 3 patients will be recruited to the next cohort (dose level)  and 
will complete [ADDRESS_1084445] of a 
loading dose of 200 mg administered on Days 1, 2 and 3 followed by a daily maintenance 
dose of 100 mg. This dose may be escalated as agreed by [CONTACT_787963] a maximum daily 
loading dose of 400 mg on Days 1, 2 and 3 followed by a maximum daily maintenance dose 
of 200 mg . The maximum daily dose that may be explored in this study will be 400 mg.  
Table 3: Possible Bemcentinib Dosing Levels Involving A Loading Dose and Daily Dose 
for Part A  
Total  
Loading Dose  over 3 days (mg)  Days 1, 2 and 3  
Loading Dose  (mg)  Daily maintenance dose  
(mg)  
600 200* 100* 
1200  400 200 
 
 
 *starting dose  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 49 of 131 
 If a patient withdraws or is withdrawn for reasons other than DLT prior to completing Cycle 1, 
the patient will be replaced  for the purposes of toxicity evaluation . 
Please refer to Figure 6 for the operating characteristics of the Dose Escalation process . 
Figure 6: The 3+3 Dose Escalation Design  
 
 
[IP_ADDRESS].  Dose Limiting Toxicity  
DLT will be assessed during the first 3 weeks of treatment with bemcentinib (Cycle 1), 
according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) [NCI CTCAE] version 4 considered unrelated to leukemia progressio n or 
intercurrent illness, and defined as any of the following:  
• CTCAE Grade 3 or 4 nausea, vomiting, or diarrhea that persists despi[INVESTIGATOR_787904].  
• Any other CTCAE Grade 3 or 4 non -hematological toxicity that is considered to be 
clinically significant and causally related to bemcentinib , excluding isolated changes 

   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 50 of 131 
 in laboratory results if no clinical significance or no clinical sequelae and adequately 
improve within 7 days.  
• Prolonged neutropenia with ANC <500 and platelet count  <[ZIP_CODE] after Day 42 from 
the start of treatment in the absence of residual leukemia . 
• Treatment discontinuation, inability to administer one or more bemcentinib loading 
dose, or inability to administer three bemcentinib maintenance doses as a result of 
bemcentinib -related toxicity.  
• Any ventricular arrhythmia.  
9.2.2.  Part B  
Following SMC review of all treatment emergent safety and efficacy data from Part A,  up to 
14 evaluable patients (up to 2 0 evaluable patients in Part B5) will be recruited into each of up 
to five cohorts ( Parts B1 , B2, B3, B4 and B5 ). Depending upon the safety profile of bemcentinib 
observed in Part A the initial starting dose in combination with cytarabine  (Part B2) or 
decitabine (Part B3), may be reduced by a single dose level (i.e. MTD -1) which may be 
evaluated in at least three subjects before introduction of the MTD or R P2D identified in Part  A. 
Recruitment into Part B5 will be overseen by [CONTACT_1034]’s study tea m or designee. The 
number of recruitment slots for patients with refractory AML , defined as no hematological 
response to last AML treatment and/or patients who have received 2 or more prior treatments 
for AML , will be restricted to 1/3 of the sample size (i.e. no more than 6 evaluable patients ).The 
study team will notify investigators when recruitment restrictions are applied . 
AML Treatment Status  
 Pre-Screening Approval 
Requirement  
One prior treatment for AML and NOT refractory  Sponsor approval not required prior 
to screening  
Two or more prior treatments for AML  Sponsor approval mandatory prior to 
screening  
Refractory AML *  Sponsor approval mandatory prior to 
screening  
 
* Refractory AML is defined as no hematological response to last AML treatment and/or patients who have received 
2 or more prior treatments for AML (see Appendix 5 of Protocol BGBC003: Modified International Working Group 
Response Criteria in Acute Myeloid L eukaemia [ Cheson  , 2003, Döhner , 2017 ]) 
9.3. Overall Study Duration and Follow Up  
The study period will consist of screening, treatment  period , Final Study Visit, and follow -up 
period . The Final Study Visit will occur 28 days after the patient  has discontinued study 
   
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084446] to follow -up. Subsequent anti -cancer therapy for AML or MDS 
will be reported in the electronic case report form (eCRF)  
9.3.1.  Screening  
Patient  eligibility for the study will be determined within [ADDRESS_1084447] be discontinued. For patients in the combination arms (Part B2, B3 or B5), if 
treatment  related toxicity requires permanent discontinuation, and the toxicity can be clearly 
assigned to one of the study treatments, the other study drug in the combination can be 
continued if it is safe to do so (investigator discretion) in the absence of disease progression 
or intolerable toxicity. The investigator may also decide to discontinue both study treatments 
at this time . 
[IP_ADDRESS] Dosing patients beyond progression  
An important clinical observation in the last decade is that immune activation does not 
necessarily result in complete cancer regression for all patients, but nonetheless, clinical 
improvements are observed. In this context and for elderly patients with R/ R AML, unfit for 
intensive chemotherapy and with no alternative treatments available for their disease, 
achieving stable disease and/or becoming transfusion independent, together with 
performance status improvement, can be viewed as a positive signal. Thus , where in the 
investigator’s opi[INVESTIGATOR_1649], the patient’s disease is considered “clinically stable” with clear 
improvement in the patient’s symptomatology and with no other treatment options available, 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 52 of 131 
 other than palliative care, it may be in the patient’s best  interests to remain on treatment with 
bemcentinib.  
Therefore, patients experiencing disease progression are permitted to continue treatment with 
bemcentinib where the investigator believes patients may continue to derive clinical benefit 
from continued tr eatment.  
Clinical benefit in this context is defined as meeting one or several of the following criteria: 
evidence of disease stabili zation after documented initial progression (patient is stably worse), 
tolerance of drug(s), absence of rapid progression based on peripheral or bone marrow blasts 
and clinical hematology and clinical chemistry parameters, maintenance of good performance 
status (PS of 2 or less and not deteriorating], absence of worsening clinical symptoms (i.e., 
no symptomatic deterioration ) and/or improvements in patient’s quality of life).  
Importantly, the decision to continue treatment must be discussed and agreed by [CONTACT_124133], the patient and the Sponsor. All decisions will be documented in writing. Patients 
dosed beyond p rogression will continue to be evaluated for potential clinical benefit and safety.  
This will not affect the time point of disease progression from the perspective of trial analysis.  
9.3.3.  Final Study Visit  
Patients should return to the study site for the Final Study Visit [ADDRESS_1084448] resolved  to <Grade 1 , stabili zed or returned to baseline . If 
necessary, f ollow up monitoring for AEs may be conducted over the telephone.  
SAEs with a suspected relationship to bemcentinib will be collected beyond the 28 -day 
follow -up period until the event is  resolved to ≤ Grade 1, stabiliz ed or returned to baseline . 
All patients that have permanently discontinued study treatment for whatever reason must be 
followed for survival. The investigator or designee must confirm with the patient at the time of 
the Final Study Visit how the patient will be followed for survival  (e.g. contact [CONTACT_787975]003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 53 of 131 
 health care provider). Survival follow -up must be conducted at least every [ADDRESS_1084449] be reported in the eCRF.  
9.4. Study Stoppi[INVESTIGATOR_787909] A reserves the right to close a site or terminate the study at any time. The 
investigator  may also terminate the study at their site at any time, provided there is reasonable 
cause for the intended termination.  This action may be taken after appropriate consultation 
with the Sponsor and the Investigator. Conditions that may warrant termination of the study or 
involvement of a study site include, but are not limited to:  
• The discovery of an unexpected, serious or unacceptable risk to patients  enrolled in 
the study  
• Failure of the investigator  to comply with the protocol and Good Clinical Practice 
(GCP ) guidelines  
• Inadequate recruitment of patients  
• Attainment of the study objectives  
• As a result of commercial considerations including discontinuation of further clinical 
development of bemcentinib in AML  
9.5. End of Study  
Except in the case  of early termination ( Section 9.4), the end of the study is defined as the 
date when all patients have an OS event, unless the Sponsor terminates OS follow -up once 
all patients have discontinued study treatment . Should the last patient enrolled to the study be 
continuing to receive bemcen tinib 52 weeks from their Cycle 1 Day 1, the Sponsor may choose 
to lock the data base to that point and prepare the clinical study report ( CSR ). Data collected 
as part of this study after this point, will be reported as an addendum to the CSR.  
A final CSR  will be prepared when the last patient has completed their Final Study Visit and 
the database is locked. The Statistical Analysis Plan (SAP ) will be finalized and signed before 
database lock.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 54 of 131 
 Patients will continue to be followed for suspected SAEs until these are  resolved to ≤ Grade  1, 
stabiliz ed or returned to baseline.  Refer to Section 15.2.2  for SAE reporting after the end of 
study.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 55 of 131 
 10. Selection of Subjects  
10.1.  Inclusion Criteria  
1. Provision of signed written informed consent  
2. Histological or cytological confirmation of : 
 AML (with the exc eption of AML M3)  
a) Part A : Patients with relapsed or refractory AML following treatment with cytotoxic 
chemotherapy (with or without hematopoietic  stem cell transplantation) or a 
targeted or biologic agent  (e.g. hypomethylatin g agent, tyrosine kinase inhibitor, 
antibody)    
b) Part B1 : Patients with AML who are unsuitable for intensive chemotherapy as a 
result of advanced age or co -morbidities . Patients should have relapsed following 
at least one line of therapy or be refractory  to such prior therapy  
c) Part B2 : Patients with diagnosed AML who are unsuitable  for intensive 
chemotherapy as a result if advancing age or co -morbidities  and who are suitable 
to receive treatment with cytarabine  
d) Part B3 : Patients with AML  who are unsuitable  for intensive chemotherapy as a 
result if advancing age or co -morbidities  who are suitable to receive treatment with 
decitabine  
MDS (with the exception of deletion 5q MDS)  
e) Part B4:  Patients with previously treated MDS  (with the exception of dele tion 5q 
MDS) including inte rmediate and high -risk patients who must have received prior 
treatment for their disease. Prior treatment may include those patients who have 
received hypomethylating agents, decitabine or other approved treatments for 
MDS.  
f) Part B5: Patients with relapsed or refractory AML who are unsuitable for intensive 
chemotherapy as a result of advanced age or co -morbidities meeting the following 
criteria:  
• Must have received at least one prior treatment for AML  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 56 of 131 
 • Are suitable to receive treatment with "low-dose" cytarabine  (LDAC). 
LDAC is defined as [ADDRESS_1084450] AML treatment and/or patients who have received 2  or more  
prior treatments for AML , will be restricted to 1/3 of the sample size (i.e. no 
more than 6 evaluable patients ). Please refer to table in Section 9.2.2 . 
3. Eastern  Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 
[Appendix 1 ] 
4. Age [ADDRESS_1084451] agree to practice highly effective methods of 
contraception  (such as hormonal implants, combined oral contraceptives, injectable 
contraceptives, intrauterine device with hormone spi[INVESTIGATOR_31151], tubal ligation, total sexual 
abstinence, vasectomy) throughout the study and for >[ADDRESS_1084452] -menopau sal status defined as 
any of the following : 
a) Natural menopause with last menses >1 year ago  
b) Radiation induced oophorectomy with last menses >1 year ago  
c) Chemotherapy induced menopause with last menses >[ADDRESS_1084453] a matche d donor and are candidates for allogeneic BM 
transplantation  
2. Pregnant or lactating  
3. History of the following cardiac conditions:  
• Congestive cardiac failure of > Class II  severity according to the NYHA ( Appendix  2: 
defined as symptomatic at less than ordinary levels of activity)  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 57 of 131 
 • Ischemic cardiac event including myocardial infarction within [ADDRESS_1084454] 
dose . Patients with prior history or ECG evidence of old myocardial infarction 
should be discussed with the Sponsor to confirm eligibility.  
• Uncontrolled cardiac disease, including unstable angina, uncontrolled hypertension 
(i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), or need to 
change medication within 6 weeks of provision of consent due to lack of BP control  
• History or presence of sustained bradycardia (≤55 beats per minute ), left bundle 
branch block, cardiac pacemaker or ventricular arrhythmia . Note: Patients 
with supraventricular arrhythmia should be discussed with Sponsor to confirm 
eligibility .  
• Family history of long QTc syndrome; personal history of long QTc syndrome or 
previous drug -induced QTc prolongation of at least Grade 3 (QTc >500 ms)  
• Presence of any  factors that increase the risk for QTc prolongation, e.g. resistant 
or inad equately treated heart failure, presence of hypokalemia or hypomagnesemia 
not corrected by, or not responding to, replacement therapy or inadequately treated 
hypothyroidism as defined by [CONTACT_516728] -stimulating hormone not within the 
expected range of the institution.  
4. Abnormal left ventricular ejection fraction on echocardiography or Multi Gated 
Acquisition Scan (MUGA) (less than the lower limit of normal for a patient of that age 
at the treating institution or <45%, whichever is lower)  
5. Current treatment wi th any agent known to cause QT prolongation and have a risk for 
Torsade s de Point es which cannot be discontinued at least five half -lives or two weeks 
prior to the first dose of study treatment . Please see Appendix [ADDRESS_1084455] of relevant 
medications  
6. Screening 12 -lead ECG with a measurable QTc F >[ADDRESS_1084456] been afebrile for 48 hours following the initiation of 
antimicrobials are eligible  
8. Inadequate liver function as demonstrated by [CONTACT_7406] ≥1.5 times the upper 
limits of normal range (ULN) or alanine aminotransferase (ALT) or aspartate 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 58 of 131 
 aminotransferase (AST) ≥2.[ADDRESS_1084457] (or ≥[ADDRESS_1084458]  or ALT in 
the presence of liver involvement by [CONTACT_787967])  
9. Inability to tolerate oral medication  
10. Existing gastrointestinal disease affecting drug absorption such as celiac disease or 
Crohn ’s disease  
11. Known lactose intolerance  
12. Requires vitamin K antagonists. Note: Patients receiving low doses prescribed to 
maintain the patency of venous access devices may be included  
13. Treatment with any of the following; histamine receptor [ADDRESS_1084459] disease  
17. Hematopoietic  stem cell transplantation within 6 months  
18. Impaired renal function as demonstrated by a creatinine clearance of <30 mL/min 
determined by [CONTACT_3158] -Gault formula  
19. Radiotherapy or chemotherapy within the [ADDRESS_1084460] dose of bemcentinib 
being administered (other than hydroxyurea)  
20. Receiving an investigational anti -cancer treatment concurrently or within 14 days or 
five half -lives (whichever is shorter) of either the parent drug or any known active 
metabolite prior to the start of bemcentinib  
21. Unresolved CTCAE >Grade 2 toxicity (other  than stab le toxicity) from previous 
anti-cancer therapy excluding alopecia  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 59 of 131 
 22. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic 
impairment) or current unstable or uncompensated respi[INVESTIGATOR_787910] u ndesirable for the patient to participate in the study or which could 
jeopardize compliance with the protocol  
23. Known a ctive, uncontrolled central nervous system (CNS) disease including CNS 
leukemia  
24. Active infection with human immunodeficiency virus (HIV), h epatitis B or C viruses – 
screening for viral infections is not required for entry to this study  
25. Major surgery within 28 days prior to the start of bemcentinib – excluding skin biopsies 
and procedures for insertion of central venous access devices  
26. Hypersen sitivity to cytarabine, decitabine or any of their excipi[INVESTIGATOR_840]  
27. Prior exposure to Astellas ASP2215  (FLT3/AXL inhibitor Gilteritinib)  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 60 of 131 
 11. Study Procedures and Assessments  
The Schedule of Events for specific parts of the study are summari zed in the following tables 
as outlined  below:  
• Part A  in Table 4 
• Parts B1 and B4  in Table 5  
• Parts B2, B3 and B5 in Table 6  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 61 of 131 
 Table 4: Part A Schedule of Events  
Cycle  1 2 >3 End of Study  
Week  1 2 3 4 5 6 >7  Visit  Screen  1 2 3 4 5 6 7 8 9 >[ADDRESS_1084461] dose  
Visit window (+/ -) days   0 0 0 0 0 0 2 1 1 2 1 
Informed consent  X            
Demographics  X            
Medical history  X            
Inclusion/exclusion  X            
ECOG  X       X   X X 
Physical examinationa X Xe    X X X   X X 
Vital signsb X X X X X X X X X X X X 
12-lead ECGc X X X X X X X X X X X X 
Serum pregnancy testd X Xe           
Clinical chemistryf X Xe X X X X X X X X X X 
Hematologyg X Xe X X X X X X X X X X 
Coagulation screenh X Xe    X X X   X X 
Urinalysis  X Xe    X X X X X X X 
Bone marrow aspi[INVESTIGATOR_337]  X       Xk   Xk  
Bone marrow aspi[INVESTIGATOR_337] 
(Pharmacodynamic ) Xi (Xi)   (Xj)   Xk   Xk  
Echocardiogram/MUGA  X          Xl  
PK blood samplingm  X X X X X X X X X X X 
Pharmacodynamic  blood 
samplingn  X X X X X X X X X X X 
Response criteriao        X   X  
Bemcentinib administrationp  X X X X X X X X X X  
Bemcentinib accountability       X X X X X X X 
Adverse events   X X X X X X X X X X X 
Concomitant medication  X X X X X X X X X X X X 
Overall survival   If the patient dies during the study period, report the date -of-death in the eCRF.  Xq 
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 62 of 131 
 a. A full physical examination, excluding gynecological and rectal examinations, will be conducted at the Screenin g and End of Study visits. A symptom -
directed examination will be conducted at selected visits  
b. Vital signs (systolic and diastolic blood pressure (BP), heart and respi[INVESTIGATOR_609921]) will be taken at every visit   
c. Triplicate 12 -lead ECGs will be taken, ≤5 minutes apart, after resting for ≥[ADDRESS_1084462] -dose (Day 1); 24 (pre 2nd dose) and [ADDRESS_1084463] -Day 1 dose (Day 
2); 48 hr (pre 3rd dose) post -Day 1 dose (Day 3); pre -dose, 2, [ADDRESS_1084464] -dose (Day 4). Patients who re -start bemcentinib following interruption for 
>[ADDRESS_1084465] be made to make ECG assessment at specified time -points  
d. For women of child -bearing potential  
e. Unless conducted as part of the screening procedures within 3 days prior to Day 1  
f. Clinical chemistr y laboratory parameters  (uric acid, electrolytes, blood urea nitrogen (BUN), total protein, total bilirubin, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), serum creatinine, creatine phosphokinase, alkaline phosphatase, albumin, calcium,  magnesium, phosphorus, 
glucose ,)  
g. Hematology laboratory parameters (full blood count including differential white cell count  and blast count , hemoglobin , hematocrit and platelets)  
h. Coagulation parameters: prothrombin time (PT) and activated partial thrombo plastin time  (APTT) 
i. Bone marrow aspi[INVESTIGATOR_787911]. If diagnostic bone marrow aspi[INVESTIGATOR_787912], a repeat (fresh) bone marrow aspi[INVESTIGATOR_787913] -1 or Day 0 (pre -dose) for pharmacodynamic  biomarker analyses  
j. Optional bone marrow aspi[INVESTIGATOR_787914].  
k. Bone marrow aspi[INVESTIGATOR_787915] 2 Day 1 (pre -dose); optional 
assessments may be performed on Day 1 of every cycle thereafter and as clinically indicated.  
l. Echocardiogram/MUGA scan Cycle 4 Day 1 ONLY  
m. Blood sampling for the determination of bemcent inib in plasma will be conducted at the following Cycle 1 time -points:  
3-day l oading  dose schedule  or no loading dose : pre-dose and 2, 4, [ADDRESS_1084466] -dose (Day 1); 24 (pre 2nd dose) and [ADDRESS_1084467] -Day 1 dose (Day 2); 
48 hr (pre 3rd dose) and 2, 4, 6, [ADDRESS_1084468] -dose (Day 3); and pre -dose (Day 4)  
A pre -dose sample will be collected at ALL study visits (including >3 Cycle 3 (up to and including Cycle 15) and End of Study) . All time -points are 
approximate, but ever y effort must be made to take  samples at specified time -points. Actual times must be recorded . Maximum sam pling time -points 
are described. P lease refer to the local Laboratory Manual for time -points required at each site   
n. Blood sampling for pharmacodynamic  biomarker analyses will involve a maximum 33 mL blood volume at Cycle 1 Day 1 and Day 4, Day 1 of each 
cycle thereafter, (up to and including Cycle 15), and End of Study visit, or a multiple number of 4.5  mL blo od samples to match the pharmacokinetic 
samples (see Table s 12-14). Please refer to the local Laboratory Manual for time -points required at each site.   
o. Assessment of clinical response (% blasts; neutrophil count; platelet count) . Response assessment should be performed by [CONTACT_787976] 5  (Cheson, 2003  and Döhner, 2017 ).  
p. Bemcentinib should be taken  on an empty stomach at a similar time each morning when they wake, or more than [ADDRESS_1084469] not died prior to the Final Study Visit should be followed for survival at ≤[ADDRESS_1084470] be reported 
for all patients in the eCRF (unless they are lost to follow -up or withdraw co nsent.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 63 of 131 
  
Table 5: Part s B1 and B4 Schedule of Events  
Cycle  1 2 >3 End of 
Study  Follow -Up 
Week  1 2 3 4 5 6 >7   
Visit  Screen  1 2 3 4 5 6 7 8 9 >[ADDRESS_1084471] 
dose   
Visit window (+/ -) days   0 0 0 0 0 0 2 1 1 2 1  
Informed consent  X             
Demographics  X             
Medical and surgical history  X             
Inclusion/exclusion  X             
ECOG  X       X   X X  
Physical examinationa X Xe    X X X   X X  
Vital signsb X X X X X X X X X X X X  
12-lead triplicate ECGc X X X X X X X X X X X X  
Serum pregnancy testd X Xe            
Clinical chemistryf X Xe X X X X X X X X X X  
Hematologyg X Xe X X X X X X X X X X  
Coagulation screenh X Xe    X X X   X X  
Urinalysis  X Xe    X X X X X X X  
Bone marrow aspi[INVESTIGATOR_337]  X       Xk   Xk   
Bone marrow aspi[INVESTIGATOR_337] ( Pharmacodynamic ) X (Xi)   (Xj)   Xk   Xk   
Echocardiogram/MUGA  X          Xl   
PK blood samplingm  X X X X X X X X X X X  
Pharmacodynamic  blood samplingn  X   X   X   X X  
Response assessmento        X   X Xo Xo 
Bemcentinib administrationp  X X X X X X X X X X   
Bemcentinib accountability       X X X X X X X  
Adverse events   X X X X X X X X X X X  
Concomitant medication  X X X X X X X X X X X X  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 64 of 131 
 Cycle  1 2 >3 End of 
Study  Follow -Up 
Week  1 2 3 4 5 6 >7   
Visit  Screen  1 2 3 4 5 6 7 8 9 >[ADDRESS_1084472] subsequent AML /MDS  treatment in 
eCRF     Xq 
Overall Survival   If the patient dies during study period, please report the date -of-death 
in the eCRF    
a. A full physical examination, excluding gynecological and rectal examinations, will be conducted at the Screening and End of Study visits. A symptom -
directed examination will be conducted at selected visits  
b. Vital signs (systolic and diastolic blood pressure (BP), heart and respi[INVESTIGATOR_149939]) will be taken  at every visit  
c. Triplicate 12 -lead ECGs will be taken, ≤5 minutes apart, after resting for ≥[ADDRESS_1084473] -dose (Day 1); 24 (pre 2nd dose) and [ADDRESS_1084474] -Day 1 dose (Day 
2); 48 hr (pre 3rd dose) post -Day 1 dose (Day 3); pre -dose, 2, [ADDRESS_1084475] -dose (Day 4). All time -points are approximate, but every effort must be 
made to make ECG assessment at specified tim e-points  
d. For women of child -bearing potential  
e. Unless conducted as part of the screening procedures within 3 days prior to Day 1  
f. Clinical chemistry laboratory parameters  (uric acid, electrolytes, blood urea nitrogen (BUN), total protein, total bilirubin, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), serum creatinine, creatine phosphokinase, alkaline phosphatase, albumin, calcium, magnesium, phosphorus, 
glucose )  
g. Hematology laboratory parameters (full bloo d count including differential white cell and blast count, hemoglobin, hematocrit and platelets)  
h. Coagulation parameters: prothrombin time (PT) and activated partial thromboplastin time  (APTT) 
i. Bone marrow aspi[INVESTIGATOR_787916]. If diagnostic bone marrow aspi[INVESTIGATOR_787912], a repeat (fresh) bone marrow aspi[INVESTIGATOR_787913] -1 or Day 0 (pre -dose) for pharmacodynamic  biomarker analyses  
j. Optional bone marrow aspi[INVESTIGATOR_787917].  
k. Bone marrow aspi[INVESTIGATOR_787918] 2 Day 1 (pre -dose) , Cycle [ADDRESS_1084476] cycle thereafter until PD is confirmed. For patients that remain on study for more than 12 months without PD, response assessments can 
be performed after every 5 cycles until the patient experiences PD or permanently withdraws from study treatment for other re asons. O ptional 
assessments may be performed at any time duri ng the study as clinically indicated.  
l. Echocardiogram Cycle 4 Day 1 ONLY  
m. Blood sampling for the determination of bemcentinib in plasma will be conducted at the following Cycle 1 time -points:  
3-day loading dose schedule  or no loading dose : pre-dose and 2, 4, [ADDRESS_1084477] -dose (Day 1); 24 (pre 2nd dose) and [ADDRESS_1084478] -Day 1 dose (Day 2); 
48 hr (pre 3rd dose) and 2, 4, 6, [ADDRESS_1084479] -dose (Day 3); and pre -dose (Day 4)  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 65 of 131 
 A pre -dose sample will be collected at ALL study visits (including ≥3 Cycle 3 (up to and includin g Cycle 15) and End of Study). All time -points are 
approximate, but every  effort must be made to take samples at specified time -points. Actual times must be recorded . Maximum sampli ng time -points 
are described. P lease refer to the local Laboratory Manual f or required time-points .  
n. Blood sampling for pharmacodynamic  biomarker analyses will involve a maximum 33 mL blood volume taken at pre -dose at Cycle 1 Day 1 and Day 4, 
Day of  each cycle thereafter (up to and including Cycle 15) and End of Study visit    
o. Assessment of response (% blasts; neutrophil count; platelet count)  until treatment failure is confirmed . Response assessment should be performed by 
[CONTACT_542333] t o the modified response criteria in Appendix 5  (Cheson, 2003  and Döhner, 2017 ) for AML and Appendix 6  (Cheson, 2006 ) 
for MDS.  
p. Bemcentinib should be taken  on an empty stomach at a similar time each morning when they wake, or more than [ADDRESS_1084480] 3 days of treatment (loading dose) and 200  mg orally daily thereafter (maintenance dose).  
q. All patients that have not died prior to the Final Study Visit should be followed for surviva l at ≤[ADDRESS_1084481] be reported 
for all patients in the eCRF (unless they are lost to follow -up or withdraw consent.  
  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 66 of 131 
 Table 6: Part s B2, B3 and B5 Schedule of Events  
Cycle  1 2 >3 End of 
Study  Follow -Up 
Week  1 2 3 4 5 6 >7   
Visit  Screen  1 2 3 4 5 6 7 8 9 >[ADDRESS_1084482] 
dose   
Visit window (+/ -) days   0 0 0 0 0 0 2 1 1 2 1  
Informed consent  X             
Demographics  X             
Medical and surgical history  X             
Inclusion/exclusion  X             
ECOG  X       X   X X  
Physical examinationa X Xe    X X X   X X  
Vital signsb X X X X X X X X X X X X  
12-lead triplicate ECGc X X X X X X X X X X X X  
Serum pregnancy testd X Xe            
Clinical chemistryf X Xe X X X X X X X X X X  
Hematologyg X Xe X X X X X X X X X X  
Coagulation screenh X Xe    X X X   X X  
Urinalysis  X Xe    X X X X X X X  
Bone marrow aspi[INVESTIGATOR_337]  X       Xk   Xk   
Bone marrow aspi[INVESTIGATOR_337] 
(Pharmacodynamic ) X (Xi)   (Xj)   Xk   Xk   
Echocardiogram/MUGA  X          Xl   
PK blood sampling ( bemcentinib )m X X X X X X X X X X X X  
Pharmacodynamic  blood samplingn X X   X   X   X X  
Response assessmento        X   X Xo Xo 
Bemcentinib administrationp  X X X X X X X X X X   
Bemcentinib accountability       X X X X X X X  
Cytarabine/decitabine administrationq  X   
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 67 of 131 
 Cycle  1 2 >3 End of 
Study  Follow -Up 
Week  1 2 3 4 5 6 >7   
Visit  Screen  1 2 3 4 5 6 7 8 9 >[ADDRESS_1084483] subsequent AML treatment in 
eCRF     X 
Overall Survival   If the patient dies during study period, please report the date -of-death in the 
eCRF  X Xr 
 
a. A full physical examination, excluding gynecological and rectal examinations, will be conducted at the Screening and End of Study visits. A symptom -
directed examination will be conducted at selected visits  
b. Vital signs (systolic and diastolic blood pressure (BP), heart and respi[INVESTIGATOR_149939]) will be taken at every visit  
c. Triplicate 12 -lead ECG s will be taken, ≤5 minutes apart, after resting for ≥[ADDRESS_1084484] -dose (Day 1); 24 (pre 2nd dose)  and [ADDRESS_1084485]-Day 1 dose (Day  2); 
48 hr (pre 3rd dose) post -Day 1 dose (Day 3); pre -dose, 2, [ADDRESS_1084486] -dose (Day 4). All time -points are approximate, but every effort must be made 
to make ECG assessment at specified time -points  
d. For women of child -bearing pot ential  
e. Unless conducted as part of the screening procedures within 3 days prior to Day 1  
f. Clinical chemistry laboratory parameters  (uric acid, electrolytes, blood urea nitrogen (BUN), total protein, total bilirubin, alanine aminotransferase (ALT), 
aspartate  aminotransferase (AST), serum creatinine, creatine phosphokinase, alkaline phosphatase, albumin, calcium, magnesium, phosphorus, 
glucose )  
g. Hematology laboratory parameters (full blood count including differential white cell and blast count, hemoglobin, hematocrit, and platelets)  
h. Coagulation parameters: prothrombin time (PT) and activated partial thromboplastin time  (APTT) 
i. Bone marrow aspi[INVESTIGATOR_787911]. If diagnostic bone marrow aspi[INVESTIGATOR_787912], a repeat (fresh) bone marrow aspi[INVESTIGATOR_787913] -1 or Day 0 (pre -dose) for pharmacodynamic  biomarker analyses  
j. Optional bone marrow aspi[INVESTIGATOR_787919].  
k. Bone marrow aspi[INVESTIGATOR_787920] 2 Day 1 (pre -dose ), Cycle [ADDRESS_1084487] cycle thereafter until PD is confirmed. For patients that remain on study for more than  12 months without PD, response assessments can 
be performed after every 5 cycles  until the patient experiences PD or permanently withdraws from study treatment for other reasons.  Optional 
assessments may be performed at any time during the study as clinically indicated.  
l. Echocardiogram to be performed at Screening and on Cycle 4 Day 1 ONLY ; or at any time during the study as clinically indicated.  
   
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 68 of 131 
 m. Blood sampling for the determination of bemcentinib in plasma will be conducted at the following Cycle 1 t ime-points : 
3-day loading dose schedule  or no loading dose : pre-dose and 2, 4, [ADDRESS_1084488] -dose (Day 1); 24 (pre 2nd dose) and [ADDRESS_1084489] -Day 1 dose (Day 2); 
48 hr (pre 3rd dose) and 2, 4, 6, [ADDRESS_1084490] -dose (Day 3); and pre -dose (Day 4)  
A pre -dose sample wil l be collected at ALL study visits (including ≥3 Cycle 3 (up to and including Cycle 15) and End of Study). All time -points are 
approximate, but every effort must be made to take sam ples at specified time -points. Actual times must be recorded . Maximum sampli ng time -points 
are described. P lease refer to the local Laboratory Manual for required time-points   
n. Blood sampling for pharmacodynamic  biomarker analyses will involve a maximum 33 mL blood volume taken at pre -dose at Cycle 1 Day 1 and Day 4,  
Day 1 of each cycle thereafter, (up to and including Cycle 15), and End of Study visit    
o. Assessment of response (% blasts; neutrophil count; platelet count)  until treatment failure is confirmed . Response assessment should be performed by 
[CONTACT_787977] 5  (Cheson, 2003  and Döhner, 2017 ) 
p. Bemcentinib should be taken  on an empty stomach at a similar time each morning when they wake, or more than [ADDRESS_1084491] 3 days of treatment (loading dose) and 200  mg orally daily thereafter (maintenance dose).  
q. Please refer to Section 12.1.[ADDRESS_1084492] not died prior to the Final Study Visit should be followed for survival at ≤[ADDRESS_1084493] be reported 
for all patients in the eCRF (unless they are lost to follow -up or withdraw consent.  
 
  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084494] provide written informed consent before any study -specific screening 
procedures are performed . Patients  who meet all inclusion/exclusion criteria will be allocated 
a study -specific patient  number.  
11.1.1.  Blinding Procedures  
This is an open -label study and c onsequently there are no blinding procedures in operation.  
11.2.  Screening  
During screening, the following procedures will be performed:  
• Obtain w ritten informed consent  
• Demographic data, including date of birth, sex, height, and race  
• Medical and surgical histor y 
• Concomitant medication  
• Physical examination, including weight  
• Echocardiogram  or MUGA scan  
• Vital sign  measurements (systolic and diastolic BP, heart and respi[INVESTIGATOR_427671])  
• Serial 12-lead ECGs , in triplicate (<5 minutes apart), performed after the patient has 
been supi[INVESTIGATOR_2525] >10 minutes)  
• ECOG performance status [Appendix 1] 
• Collection of blood sample for hematology (including neutrophil and platelet count), 
clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• Serum pregnancy test, where appropriate  
• BM aspi[INVESTIGATOR_787921] >[ADDRESS_1084495] dose 
of bemcentinib . Highly effective methods of contraception are defined as:  
• Hormonal implants, combined oral contraceptives, injectable contraceptives,  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 70 of 131 
 • An intrauterine device with hormone spi[INVESTIGATOR_31151]  
• Tubal ligation  
• True total sexual abstinence  
• Vasectomy  
If it is not possible to use one of these highly effective methods of contraception two barrier 
meth ods used in conjunction are acc eptable . 
In order to reduce the risk of tumor lysis syndrome all patients will be asked to drink up to two 
liters of fluid in the 24 -hour period prior to starting treatment with bemcentinib and on Day 0, 
Day 1 , Day 2  and Day 3 . All patients will receive treatment with allopurinol (or equivalent) for 
at least the first week of treatment or until their serum uric acid is within the normal range or 
has returned to baseline levels.  
11.3.  Treatment Period  
The following sections outline the assessments to be conducted in each part of the study . For 
Cycle 2 and beyond a visit window of +/ -48 hours is allowed for the Day 1 visit and +/ -24 hours 
for other visits, per protocol . For details of allowable windows around specific PK/PD sampling 
time-points please refer to the relevant footnotes for Tables 4-6. The timing of the Cycle [ADDRESS_1084496] -dose ECGs should approximate to the PK sampling tim e-points . Details of 
allowable windows around visits and specific procedures will be included in the eCRF 
completion guidance documentation.  
11.3.1.  Part A  
Please refer to the Schedule of Events outlined in Table 4. 
[IP_ADDRESS].  Cycle 1  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit . Patients will be intensively monitored throughout  Day 1 to Day 4 inclusive during 
Cycle 1 .  
Visit 1 ( Day 1 ): 
• Physical examination, including weight  (unless conducted as part of the screening 
procedures within 3 days prior to Day 1)  
• BM aspi[INVESTIGATOR_787922] (pre -dose) 
ONLY if the diagnostic BM aspi[INVESTIGATOR_787923] (and therefore unsuitable for PD 
analyses)  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 71 of 131 
 • Collection of additional PD biomarker blood sample (pre -dose) ONLY if BM aspi[INVESTIGATOR_787924]  
• Collection of blood sample for hematology (including n eutrophil and platelet count) and 
clinical chemistry profile (unless conducted as part of the screening procedures within 
3 days prior to Day 1)  
• Coagulation panel  (unless conducted as part of the screening procedures within 3 days 
prior to Day 1)  
• Routine u rinalysis  unless conducted as part of the screening procedures within 3 days 
prior to Day 1)  
• Serum pregnancy test, where appropriate (unless conducted as part of the screening 
procedures within 3 days prior to Day 1)  
• 12-lead ECGs  per screening procedures  (pre-dose and 2, 4, and [ADDRESS_1084497] -dose)  
• Vital signs  per screening procedures  
• Collection of PK blood sample s (at time -points outlined in Table 4) 
• Collection of pharmacodynamic  biomarker blood sample s (at time -points outlined in 
Table 4) 
• Bemcentinib administration  
Visit 2 (Day 2) : 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  ([ADDRESS_1084498] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 4) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 4) 
• Bemcentinib administration  
Visit 3 (Day 3) : 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  ([ADDRESS_1084499] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 4) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 4) 
• Bemcentinib administration  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 72 of 131 
 Visit 4 (Day 4) : 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  (pre-dose and 2, 4, and [ADDRESS_1084500] -dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 4) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 4) 
• BM aspi[INVESTIGATOR_787917] (OPTIONAL)  
• Bemcentinib administration  
Visit 5 (Day 8):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Routine urinalysis  
• Collection of PK blood sample (pre -dose)  
• Collection of pharmacodynamic  biomarker blood sample (pre -dose)  
• Bemcentinib administration  
• Bemcentinib accountability  
Interim Visit for additional ECG assessment (for patients who do not receive a loading 
dose only)  
Visit 6 (Day 15):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK b lood samples ( pre-dose ) 
• Collection of pharmacodynamic  biomarker blood samples ( pre-dose ) 
• Routine urinalysis  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 73 of 131 
 • Bemcentinib administration  
• Bemcentinib accountability   
Interim Visit for additional ECG assessment (for patients who do not receive a loading 
dose only)  
[IP_ADDRESS].  Cycle 2  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit . 
Visit 7 (Day 1 ): 
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sampl e (pre -dose)  
• Collection of pharmacodynamic  biomarker blood sample (pre -dose)  
• Bemcentinib administration  
• Bemcentinib accountability  
• BM aspi[INVESTIGATOR_787925] (pre -dose)  
unless there is clear evidence of progression  in the peripheral blood  
• Collection of additional pharmacodynamic  biomarker blood sample (pre -dose) ONLY 
if BM aspi[INVESTIGATOR_787926]   
• Clinical response criteria review according to IWG criteria (refer to Appendix 5 ) 
Visit 8 (Day 8 ) and Visit 9 (Day 15 ): 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sample (pre-dose)  
• Collection of pharmacodynamic  biomarker blood sample ( pre-dose ) 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 74 of 131 
 • Bemcentinib administration  
• Bemcentinib accountability  
[IP_ADDRESS].  Cycle 3 and Subsequent Cycles  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit . 
BM aspi[INVESTIGATOR_4026] , ECGs  and laboratory investigations  should be taken more frequently if clinically 
indicated.  
Visit >10 (Day 1 ): 
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Echocardiogram (Cycle 4 ONLY)  
• Collection of blood sample for hematology (including neutrophil and platelet count  for 
clinical response criteria review ) and clinical chemistry profile  
• Coagulation panel  
• Routine urinal ysis 
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sample (pre -dose)  up to and including Cycle 15  
• Collection of pharmacodynamic  biomarker blood sample (pre -dose)  up to and 
including Cycle 15  
• BM aspi[INVESTIGATOR_787927] (pre -dose)  unless there is clear evidence of progression in the peripheral 
blood (CYCLE 3 ONLY)  
o On Day 1 of Cycle 4 and beyond BM aspi[INVESTIGATOR_20325] e will be done only if clinically 
indicated  
• Clinical response criteria review according to IWG criteria (refer to Appendix 5 ) 
• Collection of additional pharmacodynamic  biomarker blood sample (pre -dose) ONLY 
if BM aspi[INVESTIGATOR_787926]  
• Bemcentinib administration  
• Bemcentinib accountability  
11.3.2.  Parts B1 and B4  
Please refer to the Schedule of Events outlined in Table 5. 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 75 of 131 
 [IP_ADDRESS].  Cycle 1  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit . Patients  will be intensively monitored throughout Da y 1 to Day 4 inclusive of 
Cycle  1. 
Visit 1 (Day 1):  
• Physical examination, including weight  (unless  conducted as part of the screening 
procedures within 3 days prior to Day 1)  
• BM aspi[INVESTIGATOR_787928] (pre -dose) 
ONLY if the diagnostic BM aspi[INVESTIGATOR_787923] (and therefore unsuitable for 
pharmacodynam ic analyses)  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile (unless  conducted as part of the screening procedures within 
3 days prior to Day 1)  
• Coagulation panel (unless  conducted as part  of the screening procedures within 3 days 
prior to Day 1)  
• Routine urinalysis unless  conducted as part of the screening procedures within 3 days 
prior to Day 1)  
• Serum pregnancy test, where appropriate (unless  conducted as part of the screening 
procedures w ithin 3 days prior to Day 1)  
• 12-lead ECGs per screening procedures  (pre-dose and 2, 4, and [ADDRESS_1084501] -dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 5) 
• Collection of pharmacodynamic  biomarker blood sample (pre -dose)  
• Bemcentinib administration  
Visit 2 (Day 2):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  ([ADDRESS_1084502] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 5) 
• Bemcentinib administration  
Visit 3 (Day 3):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 76 of 131 
 • 12-lead ECGs per screening procedures  ([ADDRESS_1084503] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 5) 
• Bemcentinib administration  
Visit 4 (Day 4):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures (pre -dose and 2, 4, and [ADDRESS_1084504] -dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 5) 
• BM aspi[INVESTIGATOR_787917] (OPTIONAL)  
• Bemcentinib administration  
Visit 5 (Day 8):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sample (pre -dose)  
• Routine urinalysis  
• Bemcentinib administration  
• Bemcentinib accountability  
Visit 6 (Day 15):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sample (pre -dose)  
• Routine  urinalysis  
• Bemcentinib administration  
• Bemcentinib accountability  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 77 of 131 
 [IP_ADDRESS].  Cycle 2  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit.  
Visit 7 (Day 1):  
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sampl e (pre -dose)  
• Collection of pharmacodynamic  biomarker blood samples (pre -dose)  
• Bemcentinib administration  
• Bemcentinib accountability  
• BM aspi[INVESTIGATOR_787927] (pre -dose) unless there is clear evidence of progression  in the peripheral 
blood  
• Clinical response criteria review according to IWG criteria (refer to Appendix 5  for AML 
and Appendix 6  for MDS)  
Visit 8 (Day 8) and Visit 9 (Day 15):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sample (pre -dose)  
• Bemce ntinib administration  
• Bemcentinib accountability  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 78 of 131 
 [IP_ADDRESS].  Cycle 3 and Subsequent Cycles  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit.  
BM aspi[INVESTIGATOR_787929] 2 Day 1 (pre -dose), Cycle [ADDRESS_1084505] cycle thereafter until PD 
is confirmed. For patients that remain on study for more than 12 months without PD, response 
assessments can be performed after every 5 cycles until the patient experiences PD  or 
permanently withdraws from study treatment for other reasons .  
Optio nal assessments may be performed at any time during the study as clinically indicated.  
Visit >10 (Day 1):  
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Echocardiogram (Cycle 4 ONLY)  
• Collection of blood sample for hematology (including neutrophil and platelet count for 
clinical response criteria review) and clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening p rocedures  
• Collection of PK blood sample (pre -dose)  up to and including Cycle 15  
• Collection of pharmacody namic  biomarker blood samples (pre -dose)  up to and 
including Cycle 15  
• BM aspi[INVESTIGATOR_787927] (pre -dose)  as per relevant Schedule of Events ( Table 5) in Section 11   
• Clinical response criteria review according to IWG criteria (refer to Appendix 5  for AML 
and Appendix 6  for MDS)  
• Bemcentinib administration  
• Bemcentinib accountability  
11.3.3.  Part B2 , Part B3  and Part B5 
Please refer to the Schedule of Events outlined in Table 6, Section 12.1.2  for cytarabine 
administration and Section 12.1.3  for decitabine administration.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 79 of 131 
 To accommoda te the dosing schedules of decitabine and cytarabine patients will need to 
attend the clinic / unit more frequently than required by [CONTACT_787978]/ assessment schedules of 
bemcentinib . Patients are only required to take bemcentinib capsules at clinic/ unit on those 
study days where study related procedures are being conducted.  
In Part B2 and Part B5, bemcentinib should be administered prior to cytarabine ( i.e. 
approximately 30 minutes)  and in Part B3, decitabine should be administered within 
30 minutes of the bemcentinib dose .  
Please refer to the Schedule of Events outlined in Table 6. Cytarabine  will be administered at 
a dose of 20 mg administered subcutaneously twice daily for up to ten consecutive days 
repeated approximately every 28 days .  
Decitabine will be administered at a dose of 20 mg/m2 body surface area by [CONTACT_744370] 1 hour repeated daily for 5 consecutive days  (i.e., a total of 5 doses per treatment 
cycle).  
[IP_ADDRESS].  Cycle 1  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit . Patients will be intensively monitored throughout Day 1 to Day 4 inclusive of 
Cycle  1. 
Visit 1 (Day 1):  
• Physical examination, including weight  (unless  conducted as part of the screening 
procedures within 3 days prior to Day 1)  
• BM aspi[INVESTIGATOR_787928] (pre -dose) 
ONLY if the diagnostic BM aspi[INVESTIGATOR_787930] (and therefore unsuitable for 
pharmacodynamic  analyses)  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile (unless  conducted as part of the screening procedures within 
3 days prior to Day  1) 
• Coagulation panel (unless  conducted as part of the screening procedures within 3 days 
prior to Day 1)  
• Routine urinalysis unless  conducted as part of the screening procedures within 3 days 
prior to Day 1)  
• Serum pregnancy test, where appropriate (unless  conducted as part of the screening 
procedures within 3 days prior to Day 1)  
• 12-lead ECGs per screening procedures  (pre-dose and 2, 4, and [ADDRESS_1084506] -dose)  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 80 of 131 
 • Vital signs per screening procedures  
• Collection of PK blood samples  for bemcentinib and cytarabine  analysis (at time -points 
outlined in Table 6 as appropriate ) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Bemcentinib administration  
• Commence c ytarabine  (Part B2) or decitabine (Part B3) administration  and continue 
per local practice  
Visit 2 (Day 2):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  (24, and [ADDRESS_1084507] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 6) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Bemcentinib administration  
Visit 3 (Day 3):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  ([ADDRESS_1084508] Day 1 dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 6) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Bemcentinib administration  
Visit 4 (Day 4):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• 12-lead ECGs per screening procedures  (pre-dose and 2, 4, and [ADDRESS_1084509] -dose)  
• Vital signs per screening procedures  
• Collection of PK blood samples (at time -points outlined in Table 6) 
• Collection of pharmacody namic  biomarker blood samples (at time -points outlined in 
Table 6) 
• BM aspi[INVESTIGATOR_787931] (OPTIONAL)  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 81 of 131 
 • Bemcentinib administration  
Visit 5 (Day 8):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Routine urinalysis  
• Collection of PK blood sample (pre -dose)  
• Collection of pharmacody namic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Bemcentinib administration  
• Bemcentinib accountability  
 
Visit 6 (Day 15):  
• Physical examination, including weight  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood samples ( pre-dose ) 
• Collection of pharmacodynamic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Routine urinalysis  
• Bemcentinib administration  
• Bemcentinib accountability  
[IP_ADDRESS].  Cycle 2  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit.  
Visit 7 (Day 1):  
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 82 of 131 
 • Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK blood sampl e (pre -dose)  
• Collection of pharm acodynamic biomarker blood sample (pre -dose)  
• Bemcentinib administration  
• Bemcentinib accountability  
• BM aspi[INVESTIGATOR_787932] (pre -dose) unless there is clear evidence of progression  in the peripheral 
blood  
• Clinical response criteria review according to IWG criteria (refer to Appendix 5 ) 
Visit 8 (Day 8) and Visit 9 (Day 15):  
• Collection of blood sample for hematology (including neutrophil and platelet count) and 
clinical chemistry profile  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening procedures  
• Collection of PK  blood sample (pre -dose)  
• Collection of pharm acodynamic  biomarker blood samples (at time -points outlined in 
Table 6) 
• Bemcentinib administration  
• Bemcentinib accountability  
[IP_ADDRESS].  Cycle 3 and Subsequent Cycles  
In addition to the assessments below, AEs and concomitant medications will be recorded on 
each visit.  BM aspi[INVESTIGATOR_787933] 2 Day 1 (pre -dose), Cycle [ADDRESS_1084510] cycle thereafter until 
PD is confirmed. For patients that remain on study for more than 12 months without PD, 
response assessments can be performed after every 5  cycle s until the patient experiences 
PD or permanently withdraws from study treatment for other reasons.  
Optional asses sments may be performed at any time during the study as clinically indicated.  
 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 83 of 131 
 Visit >10 (Day 1):  
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Echocardiogram (Cycle 4 ONLY)  
• Collection of blood sample for hematology (including neutrophil and platelet count for 
clinical response criteria review) and clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• 12-lead ECGs per screening procedures  
• Vital signs per screening p rocedures  
• Collection of PK blood sample (pre -dose)  
• Collection of pharm acodynamic  biomarker blood sample (pre -dose)  
• BM aspi[INVESTIGATOR_787932] (pre -dose)  as per relevant Schedule of Events ( Table 6 ) in Section 11  
• Clinical response criteria review  if BM aspi[INVESTIGATOR_787934] 
(refer to Appendix  5) 
• Bemcentinib administration  
• Bemcentinib accountability  
11.4.  Final Study Visit  
The following assessments will be carried out for every patient enrolled into the study [ADDRESS_1084511] dose of study medication or at study withdrawal:  
• Collection of blood sample for hematology (including neutrophil and platelet count  for 
clinical response criteria review ) and clinical chemistry profile  
• Coagulation panel  
• Routine urinalysis  
• Recording of AEs 
• Concomitant medications  
• Physical examination, including weight  
• ECOG performance status [ Appendix 1] 
• Vital signs  per screening procedures  
• 12-lead ECGs per screening procedures  
• Collection of PK blood sample  
• Collection of pharm acodynamic  biomarker blood sample  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 84 of 131 
 • Bemcentinib accountability  
11.5.  Survival Follow -up 
• All patients must have follow -up at ≤[ADDRESS_1084512] to follow -up. 
• All subsequent therapi[INVESTIGATOR_787935].  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084513] local practi ce up to a maximum dose 
of 20 mg/m2 body surface area by [CONTACT_162141] 1 hour, repeated daily for 5 
consecutive days (i.e., a total of 5 doses per treatment cycle) .  
12.1.  Treatment Schedule and Administration  
12.1.1.  Bemcentinib  
In Part A, the starting dose of bemcentinib (Cohort 1) will be 200 mg on Cycle 1, Days 1, 2 
and 3 (loading dose), followed by a daily maintenance dose of [ADDRESS_1084514]  
the cytarabine  or decitabine treatment cycle described in Section 12.1.2 .  
The bemcentinib dose in Part B5 (combination with low dose cytarabine) will be [ADDRESS_1084515] 3 days of treatment (loading dose) and 200  mg orally daily thereafter 
(maintenance dose).  
Patients will record their dosing at home in a dosing diary that will be reviewed regularly by 
[CONTACT_7893]. Patients will be instructed as to the imp ortance of following the dosing 
instructions they have been provided with, and for maintaining an accurate and up to date 
dosing record . Patients will also be instructed to bring their dosing diary and all bemcentinib 
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084516] practice (i.e. 
20 mg/m2 twice daily for [ADDRESS_1084517] period of <1 month according to persisting 
myelosuppression). Cytarabine should be administered approximately [ADDRESS_1084518] Characteristics (SmPC) and in accordance 
with local treatment guidelines . 
Cytarabine  is considered to be standard of care for these patients and will not be supplied or 
reimbursed by [CONTACT_144273] A. 
12.1.3.  Decitabine  
In Part B3 decitabine (Dacogen®) will be administered per standard local practi ce up to a 
maximum dose of 20 mg/m2 body surface area by [CONTACT_162141] 1 hour, repeated 
daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle) . The total d aily dose 
must not exceed 20 mg/m2 and the total dose per treatment cycle must not exceed 100 mg/m2. 
The cycle should be repeated every 4 weeks depending on the patient's clinical response and 
observed toxicity . It is recommended that patients be treated f or a minimum of 4 cycles; 
however, a complete or partial remission may take longer than [ADDRESS_1084519] of care for these patients and will 
not be supplied or reimbursed by [CONTACT_144273] A. 
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084520] resolved to  Grade <1 or to baseline for treatment to recommence . For Grade 1 or 
Grade 2 (tolerable) toxicity, the patient may resume dosing at the same dose level . For 
>Grade  2 (intolerable) toxicity, the patient may resume  dosing at a dose level defined by [CONTACT_787979](s) of prior toxicity as outlined in Table 7. 
A maximum of two dose reductions are permitted.  
Table 7: Dose Modification of Bemcentinib  Daily  Dose for Toxicity  
Grade (CTCAE)  Recommended Dose Modification  
Grade 1 and Grade 2 (tolerable)  
Any occurrence  Maintain dose if toxicity is tolerated by [CONTACT_144295] 2 (intolerable)  
1st or 2nd occurrence  
of same adverse event  Interrupt treatment until toxicity returns to baseline, 
Grade [ADDRESS_1084521] occurrence  Discontinue permanently  
Notes:  
• Treatment interruption for bemcentinib -related toxicity should be limited to 14 days  
• Dose reduction below 100 mg daily is not possible  (a single capsule contains 100 mg bemcentinib ) 
• Patients being considered for dose reduction or permanent discontinuation of bemcentinib , should be 
discussed with the Medical Monitor  
 
 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 88 of 131 
 If after a 14-day delay, toxicity has not resolved to Grade <1 or to baseline the patient should 
be withdrawn from the study.  
In clinical study BGBC001 bemcentinib  exhibited evidence of exposure -related QTc 
prolongation , and it is anticipated that QTc prolongation  could be dose -limiting in this  study . In 
order to reduce the risk of QTc prolongation , all efforts should be made to maintain the 
patient’s  serum potassium levels at > 4 mmol/ L during treatment with bemcentinib and for 
2 weeks following completion of therapy. Serum calcium and magnesium should be measured 
and reasonable efforts made to maint ain at normal levels throughout treatment . Patients  with 
a QTc of >480 ms  should be closely monitored on the clinical trial unit until their QTc falls 
below 480 ms and their  electrolytes should be measured and corrected as necessary.   
If a patient experiences QTc prolongation  despi[INVESTIGATOR_787936] , bemcentinib dosing should be modified as outlined in Table 8. All values refer to the 
mean of triplicate serial ECG recordings . If a patient experiences a ventricular arrhythmia at 
any time, they should be withdrawn from the study . 
Table 8: Dose Modification of Bemcentinib  Daily Dose for QTc Prolongation  
QTcF  Recommended Bemcentinib  Dose Modification  
Grade 1 (451 -480 ms)  
Any occurrence  No dose modification required  
Grade 2 (481 -500 ms)   
1st occurrence  
  Continue dosing and conduct weekly ECGs;  
i)   if QTcF reduces to ≤Grade 1 by 14 days from initial 
recording, no dose modification is required  
ii)  if QTcF does not reduce to ≤Grade 1 by 14 days from initial 
recording, dose reduce by 100 mg  
≥2nd occurrence   
(without dose 
modification)  Repeat procedure for “1st occurrence”   
≥2nd occurrence   
(at reduced dose)  
  Continue d osing and conduct weekly ECGs;  
i)   if QTcF reduces to ≤Grade 1 by 14 days from initial 
recording, no further dose modification is required  
ii)   if QTcF does not reduce to ≤Grade 1 by 14 days from 
initial recording, interrupt treatment for ≤14 days  
- if QTcF reduces to ≤Grade 1, no dose modification is 
required  and dosing can recommence; if treatment 
interruption is required on more than 2 occasions at 
reduced dose, dose reduce by [CONTACT_20904] 100 mg or 
discontinue treatment if dose reduction is not possible  
- if QTcF does not reduce to ≤Grade 1, dose reduce by 
[CONTACT_20904] 100 mg or discontinue treatment if dose reduction 
is not possible  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 89 of 131 
  
≥Grade 3 ( >501 ms)   
1st occurrence  Interrupt treatment for ≤14 days;  
i) if QTcF reduces to ≤Grade 1, dose reduce by 100 mg or 
discontinue treatment if dose reduction is not possible  
ii) if QTcF does not reduce to ≤Grade 1, discontinue treatment  
2nd occurrence   Discontinue permanently  
Ventricular arrhythmia  
1st occurrence  Discontinue permanently  
Notes:  
• Serum calcium, magnesium and potassium should be measured regularly whilst receiving bemcentinib ; all 
abnormal results should be corrected ; check for use of concomitant medication that are associated with QT 
prolongation.  
• The mean QTcF value from  triplicat e ECG  readings should be used when considering dose modification  
• Treatment interruption for bemcentinib -related toxicity should be limited to 14 days  
• Dose reduction below 100 mg daily is not possible (a single capsule contains 100 mg bemcentinib ) 
• Patients being considered for dose reduction or permanent discontinuation of bemcentinib should be 
discussed with the Medical Monitor  
 
12.3.  Concomitant Medication and Procedures  
All prescription, non -prescription, or over -the-counter medications including herbal remedies 
given to, or taken by, the patient at entry and during the study must be clearly documented in 
the eCRF.  
The patients must be instructe d that no additional medication will be allowed without the prior 
consent of the investigator . Any medication considered necessary for the patient’s safety and 
well-being may be given at the discretion of the investigator . Hematopoietic  growth factors 
may be administered for the treatment of AEs such as neutropenic infections but should not 
be used to maintain the dose intensity of bemcentinib in Part A . Patients who have evidence 
of treatment benefit after >[ADDRESS_1084522] of these 
prohibited medications is provided in Appendix 3. Patients being treated with antacid histamine 
receptor 2 inhibitors or proton pump inhibitors within 3 days of administration of bemcentinib 
will be excluded . The Investigator may initiate treatment with these medications during the 
study, providing they are taken in the evening.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 90 of 131 
 12.4.  Continuation of Treatment  
It is acknowledged that the R/R AML setting is a high unmet need for effective therapi[INVESTIGATOR_014], more 
so for those elderly patients unsuitable for intensive chemotherapy enrolled into this study. 
Unlike intensive chemotherapy approaches where a clinical response may be observed 
relatively early in the treatment phase, the Sponsor has observed clinical responses occurring 
later in patients treated with bemcentinib in its immunotherapeutic mode of action when given 
as monotherapy or in combination with other agents.  Given that AXL mediates multiple 
survival mechanisms used by [CONTACT_282628] (chemotherapy drug resistance, immune evasion) and 
given AXL is found at high levels on immune cells in proximity to some tumors and on the 
tumor cells themselves, it is not unexpected t hat it may take longer to observe some clinical 
responses in some patients as bemcentinib inhibits the expression of AXL and allows the 
body’s own immune system to kill tumor cells. This would explain both the early (cytotoxic like 
consequences of reversal  of EMT) and the late (activation of innate immune anti -tumor 
responses) responses which have been observed in this study. Therefore, i t is recommended 
that study treatment is administered for at least [ADDRESS_1084523] be 
discontinued from the study if any of the following criteria are met:  
• Significant p atient  non-compliance with the protocol, as agreed by [CONTACT_787980]  
• Patient  lost to follow -up 
• Termination of the study by [CONTACT_456]  
• Patient  experiences an unacceptable toxicity that precludes them from continuing 
in the study  e.g. patient experiences a ventricular arrhythmia (see Section 12.2 .1), 
as agreed by [CONTACT_31376]  
• Lack of adequate recovery from a first cycle DLT, see Section [IP_ADDRESS]  
• Failure of toxicity  to adequately resolve , as outlined in Table 7 
• Female patient  becomes pregnant  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 91 of 131 
 • Patient  experiences PD (unless in the opi[INVESTIGATOR_871], they continue to 
derive clinical benefit  and are permitted to continue on study after discussion and 
agreement between investigator, the patient and Sponsor. All decisions will be 
documented in writing).  
Note:  Clinical benefit in this context is defined as meeting one or several of the 
following  criteria: evidence of disease stabili zation  after documented initial progression 
(patient is stably worse), tolerance of drug(s), absence of rapid progression based on 
peripheral or bone marrow blasts and clinical hematology and clinical chemistry 
paramet ers, maintenance of good performance status (PS of 2 or less and not 
deteriorating], absence of worsening  clinical symptoms (i.e., no symptomatic 
deterioration ) and/or improvements in patient’s quality of life).  This will not affect the 
time point of disease progression from the perspective of trial analysis.  
• Patient and/or investigator decide that it is in the patient’s best interest to withdraw 
from study treatment or the patient withdraws consent  
AEs resulting in discontinuation will be followed as outlined in Section 9.3.4 . 
Patients who discontinue during the DLT assessment period (Part A), for any reason other 
than a DLT, will be replaced . All other patients who discontinue study treatment will not be 
replaced.  
If a patient  discontinues study treatment  prior to study completion, and for reasons other than 
progression or non -tolerability, every effort should be made to conduct the Final Study Visit 
assessme nts as outlined in Section 11.5. The reason for the patient’s withdrawal from th e 
study must be recorded in the  eCRF. Patients that permanently discontinue either bemcentinib 
or the combination agent must continue to undergo all study assessments until all study 
treatments have been permanently discontinued after which they must attend the Final Study 
Visit.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 92 of 131 
 13. Study Assessments  
Study assessments will be conducted according to the relevant Schedule of Events 
(Tables  4-6) in Section 11. 
13.1.  Clinical Safety Assessments  
Before being entered into the study, patients will be assessed to ensure that eligibility criteria 
are met . Patients not meeting the criteria must not be entered into the study.  
The following tests and assessments will be performed at times specified in the relevant 
Schedule of Events (Tables 4-6) in Section 11 and at any other time required in the opi[INVESTIGATOR_13046] : 
• Serum pregnancy test on women of childbearing potential (Screening only)  
• Physical examination  
• Vital sign measurements (systolic and diastolic BP, heart and respi[INVESTIGATOR_427671] ) 
• Serial 12 -lead ECGs, in triplicate ( <5 minutes apart), performed after the patient has 
been supi[INVESTIGATOR_2525] >10 minutes)  
• AE and SAE recording  
• Concomitant medication and procedures recording  
• Echocardiogram  or MUGA scan  
13.1.1.  Resting 12 -lead ECG  
For timing of individual measurements please refer to relevant Schedule of Events 
(Tables  4-6) in Section 11. 
Twelve -lead ECGs will be obtained after the patient has rested in a supi[INVESTIGATOR_19636] 
>10 minutes in each case . All 12 -lead ECGs should be recorded while the patient is in the 
supi[INVESTIGATOR_2547] . The investigator or designated physician will review the pape r copi[INVESTIGATOR_787937] 12 -lead ECGs on each of the study days when they are collected . ECGs will be  
conducted  in triplicate  and performed <5 minutes apart . 
ECGs will be recorded at 25 mm/sec . A clinically significant ECG  finding  must be recorded  as 
part of the medical history , if observed prior to start of dosing , and as an AE post-dose, where 
the finding represents a change from baseline.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 93 of 131 
 13.1.2.  Physical Examination  
The physical examination will be symptom -directed and will exclude rectal and gynecological 
(where applicable) examinations.  
13.1.3.  Vital Signs  
For timing of individual measurements please refer to relevant Schedule of Events 
(Tables  4-6) in Section 11. 
BP and HR will be measured using a BP recording device with an appropriate cuff size . 
Measurements will be made after the patient has been resting supi[INVESTIGATOR_2525] >[ADDRESS_1084524] Symptomatology  
Symp toms reported spontaneously by [CONTACT_787981] . 
Symptoms reported will be reviewed by [CONTACT_787982] 
a change from baseline or a new symptom reported. Please note that every eff ort should be 
made to report the actual medical condition rather than a symptom in the eCRF (see 
Section  15.1.1  Adverse Event for guidance).   
13.2.  Laboratory Safety Assessments  
Blood and urine samples will be taken at times specified in the relevant Schedule of Events 
(Tables 4-6) in Section 11, and at any other time required in the opi[INVESTIGATOR_871] , 
and analy zed at the designated local laboratory.  
13.2.1.  Hematology and Clinical Chemistry  
Blood samples for the determination of clinical chemistry, hematology  and coagulation  
parameters to be me asured are outlined in Table 9 . 
Table 9: Hematology , Clinical Chemistry  and Coagulation  Parameters  
Biochemistry  Hematology  
Bilirubin  Hemoglobin  
Aspartate aminotransferase (AST)  Mean cell hemoglobin (MCH)  
Alanine aminotransferase (ALT ） Mean corpuscular hemoglobin concentration (MCHC)  
Alkaline phosphatase (ALP ） Total white cell count  
Creatine phosphokinase  (CK)  Differential white cell count  
Creatinine  Platelets   
Peripheral blast percentage  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 94 of 131 
 Biochemistry  Hematology  
Albumin  Coagulation  
Total protein  Prothrombin time (PT)  
Potassium (K)  Activated Partial Thromboplastin Time (APTT)  
Sodium (Na)   
Calcium (Ca)  
Magnesium  (Mg)  
Glucose    
Inorganic phosphate (IP)  
Uric acid   
Additional parameters may be performed as clinically indicated and per local practice  
 
 
13.2.2.  Urinalysis  
Dipstick urinalysis for measurement of the parameters outlined in Table 10 will be conducted 
by [CONTACT_12082] : 
Table 10: Urinalysis Parameters  
pH Nitrite  
Glucose  Blood  
Proteins  Leukocytes  
Ketones  Specific gravity  
Bilirubin  Urine microscopy  (if indicated ) 
Additional parameters may be performed as clinically indicated and per local practice  
 
 
13.3.  Pharmacokinetic Assessments  
Venous blood samples for the determination of concentrations of bemcentinib (all Parts) in 
plasma will  be taken at times specified in the relevant Schedule of Events ( Table s 4-6) in 
Section 11. Detailed procedures for the collection, processing, storage and shipment of the 
samples will be provided in the Study Laboratory Manual.  
Table 11: Bemcentinib PK Sampling Time Points and Permitted Windows  
Study Day  Time Point (hr)  Permitted Time Window  
Cycle 1 Day 1  Pre-dose   
 2.0 +/-15 mins (from C1D1 dose)  
 4.0 +/- 30 mins (from C1D1 dose)  
 6.0 +/- 45 mins (from C1D1 dose)  
Cycle 1 Day 2  24.0 +/-2 hrs (from C1D1 dose)  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 95 of 131 
  30.0 +/-3 hrs (from C1D1 dose)  
Cycle 1 Day 3  48.0 (0)  +/-4 hrs (from C1D1 dose)  
 2.0 +/-15 mins (from C1D3 dose)  
 4.0 +/- 30 mins (from C1D3 dose)  
 6.0 +/- 45 mins (from C1D3 dose)  
 8.0 +/-1 hrs (from C1D3 dose)  
Cycle 1 Day 4  Pre-dose  +/-2 hrs (from C1D3 dose)  
Day 1 of each cycle  up to and 
including Cycle 15  Pre dose   
EOS   As collected - not time specific  
 
 
13.3.1.  Determination of Bemcentinib  Concentration in Plasma  
Plasma samples for determination of bemcentinib concentration will be analy zed by 
[CONTACT_787983]’s  Bioanalytical Services vendor using the validated LC/MS/MS method.  
13.4.  Clinical Efficacy Assessments  
All patients must undergo baseline disease assessments at Screening (peripheral blood and 
BM). Response assessments will be performed  at Cycle 2 Day 1  (pre-dose) , Cycle [ADDRESS_1084525] not  experienced PD, will undergo response assessment 
every 5 cycles until PD is confirmed. A BM assessment may be performed at any time during 
the study as clinically indicated  as outlined in the relevant Schedule of Events ( Tables 4-6) in 
Section 11. Response assessment will be performed by [CONTACT_787984] ( Cheson, 2003  and Döhner, 2017 ). Please refer to 
Appendix 5 . 
The assessment of the clinical efficacy of bemcentinib in AML will be made , according to the 
revised recommendations of the IWG in AML [ Cheson , 2003  and Döhner, 2017 ] as follows:   
• Assessment of the % of blasts in a peripheral blood and BM aspi[INVESTIGATOR_26679]  
• Measurement of absolute neutrophil count ( ANC ) 
• Measurement of Platelet count  
• Red cell transfusion requirement  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 96 of 131 
 The assessment of clinical efficacy of bemcentinib in patients with MDS will be made 
according to the modified IWG response criteria in myelodysplasia [ Cheson, 2006 ]. Please 
refer to Appendix 6 . 
• Assessment of the % of blasts in a peripheral blood and BM aspi[INVESTIGATOR_26679]  
• Measurement of ANC  
• Measurement of Platelet count  
• Red cell transfusion requirement  
BM aspi[INVESTIGATOR_787938] . Wherever 
possible, an aliquot of BM aspi[INVESTIGATOR_787939] 
(see Section 13.5.1 ). 
13.5.  Pharmacodynamic and Predictive Biomarkers  
The effects of bemcentinib on pharmacodynamic endpoints of AXL inhibition will be 
determined in BM aspi[INVESTIGATOR_787940] :  
• To identify and evaluate potential predictive biomarkers, e.g. sAXL and other 
associated soluble biomarkers. Pre -treatment levels of biomarkers will be c orrelated 
with clinical endpoints . 
• To establish the effects of bemcentinib on relevant biological endpoints  in peripheral 
blood (including sAXL PBMC) and BM samples.  
• To assess pharmacodynamic biomarkers in tissue and blood to support the clinical 
development of bemcentinib.  
• To evaluate other biomarkers relevant to the investigational agents for exploratory 
purposes.  
• Effect of bemcentinib on AXL, sAXL  and p AXL and downs tream effectors of AXL 
signaling, such as  Akt, pAkt, Erk, pErk, SLFN11, Bcl2, Puma by [CONTACT_382612] 
(e.g. FCM, western blotting, proteomics, transcriptomics)  
• Effect of bemcentinib on gene expression by [CONTACT_382612] (e.g. FCM, western 
blotting,  proteomics, transcriptomics, quantitative PCR, DNA -methylation analysis)  
• Effect of bemcentinib on relevant immune cell populations.  
• Effect of bemcentinib on the spectrum of mutations present within the cancer cell 
population by [CONTACT_787962].  
• To explor e the correlation between baseline biomarker levels and clinical endpoints.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 97 of 131 
 Biomarker  samples  will be collected at the time -points  outlined in the relevant Schedule of 
Events (Tables 4-6) in Section 11. Detailed procedures for the collection, processing, storage 
and shipment of the samples will be provided in the Study Laboratory Manual.   
13.5.1.  Bone Marrow Aspi[INVESTIGATOR_787941], as 
outlined in Section 13.4, will be processed for the pharm acodynamic  investigation of AXL 
inhibition by [CONTACT_787985] .  
A BM aspi[INVESTIGATOR_787942] 1 Day 4 from patients who consent to this optional 
procedure.  
The samples collected will be analy zed for the following:  
• To identify and evaluate potential predictive biomarkers . Pre-treatment levels of 
biomarkers  will be correlated with clinical endpoints.  
• To evaluate other biomarkers relevant to the investigational agents for exploratory 
purposes.  
• Effect of bemcentinib on AXL, sAXL  and p AXL and downstream effectors of AXL 
signal ing, such as  Akt, pAkt, Erk, pErk, SLFN11  Bcl2, Puma  by [CONTACT_382612] 
(e.g. western blotting, proteomics, transcriptomics)  
• Genomic analysis of normal tissue, and of cancer cells prior to and during treatment 
with bemcentinib , to investigate whether the spectrum of mutations present within the 
cancer cell population changes with bemcentinib treatment  
• BM mononuclear cells (CD34+) will be analy zed by [CONTACT_787986]-Batalla, 2013  
13.5.2.  Pharmacodynamic Blood Samples  
Blood samples will be collected at the time -points outlined in the relevant Schedule of Events 
(Tables 4-6) in Section 11.  
• To assess pharmacodynamic biomarkers in tissue and blood to support the clinical 
development of bemcentinib  
• Effect of bemcentinib on AXL, sAXL  and p AXL and downstream effectors of AXL 
signaling, such as  Akt, pAkt, Erk, pErk, SLFN11  Bcl2, Puma  by [CONTACT_382612] 
(e.g. FCM, western blotting, proteomics, transcriptomics)  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 98 of 131 
 13.6.  Volume of Blood and Bone Marrow Sampling  
The approximate , maximum volume of blood and BM aspi[INVESTIGATOR_787943]:  
Table 12: Volume of blood and BM aspi[INVESTIGATOR_787944] 1  
Assessment  Sample 
volume 
(mL)  Part A  Part B  
n Total volume 
(mL)  n Total volume (mL)  
Pharmacokinetics  4.5 14 63 14 63 
Pharmacodynamics  33 2 66 2 66 
Coagulation  5 4 20 4 20 
Clinical chemistry  5 7 35 7 35 
Hematology  2.5 7 17.5 7 17.5 
Total blood volume (mL) for screen and 
Cycle 1  201.5  201.5  
Pharmacodynamics  20 1(3)a 20(60)  1(3)a 20(60)  
Clinical efficacy assessmentb 1 1 1 1 1 
Total BM volume (mL) for screen and 
Cycle 1  20(60)  20(60)  
 
maximum of 3 samples if patient consents to optional BM aspi[INVESTIGATOR_787945] 4 and diagnostic BM aspi[INVESTIGATOR_787946]  
b 1 mL aliquot of total 20  mL BM aspi[INVESTIGATOR_787947] 13: Volume of Blood and BM aspi[INVESTIGATOR_787900] 2  
Assessment  Sample 
volume 
(mL)  Part A  Part B  
n Total volume 
(mL)  n Total volume (mL)  
Pharmacokinetics  4.5 3 13.5 3 13.5 
Pharmacodynamics  33 1 33 1 33 
Coagulation  5 1 5 1 5 
Clinical chemistry  5 3 15 3 15 
Hematology  2.5 3 7.5 3 7.5 
Total blood volume (mL) for Cycle 2  74 74 
Pharmacodynamics  20 1 20 1 20 
Clinical efficacy 
assessmenta 1 1 1 1 1 
Total BM volume (mL) for Cycle 2  20 20 
a 1 mL aliquot of total 20  mL BM aspi[INVESTIGATOR_787947] 14: Volume of Blood and BM aspi[INVESTIGATOR_787901] >3 (up to 
and including Cycle 15 for PK and Blood Pharm acodynamic s) & at Final Study Visit  
Assessment  Sample 
volume 
(mL)  Part A  Part B  
n Total volume 
(mL)  n Total volume (mL)  
Pharmacokinetics  4.5 1 4.5 1 4.5 
Pharmacodynamics  33 1 33 1 33 
Coagulation  5 1 5 1 5 
Clinical chemistry  5 1 5 1 5 
Hematology  2.5 1 2.5 1 2.5 
Total blood volume (mL) per Cycle & 
Final Visit  50 50 
Pharmacodynamics  20 1 20 1 20 
Clinical efficacy 
assessmenta 1 1 1 1 1 
Total BM volume (mL) per Cycle  20 20 
1 mL aliquot of total 20  mL BM aspi[INVESTIGATOR_778649]; optional assessment performed as clinically indicated  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084526] (IMP) bemcentinib  must be stored in a  secure location . 
Accountability for study treatment is the responsibility of the investigator . The 
investigator /designee must ensure that the IMP will only be dispensed to patients in 
accordance with the protocol and that any unused IMP will be disposed of or, if unopened, 
returned in accordance with the written instructions of the sponsor.  
Study staff should refer to the sponsor’s Directions for Handling and Administration (DHA) 
document for specific instructions regarding the handling, storage,  dispensing and destruction 
of the IMP.  
Bemcentinib has been manufactured according to appropriate Good Manufacturing Practice 
(GMP) standards . Bemcentinib will be labelled in compliance with GMP Annex 13 
requirements , Food and Drug Administration ( FDA) requirements  and local regulatory 
guidelines.  
14.1.1.  Bemcentinib  
Bemcentinib will be supplied in hydroxypropyl methylcellulose (HPMC) capsules at a dose 
strength of 100 mg for oral dosing . Please refer to Section 4 of the current version of the 
bemcentinib IB for additional information on the physical, chemical and pharmaceutical 
properties of bemcentinib . 
[IP_ADDRESS].  Bemcentinib Storage  
Bemcentinib will be shipped to the site and must be stored at the site in a secure location 
under ambient temperature conditions  (<25 °C/ <77 °F) .    
Detailed i nstructions  for the storage of dispensed IMP at home will be provided to every patient 
enrolled in the clinical study.  
[IP_ADDRESS].  Bemcentinib Accountability  
The investigator /designee must  maintain complete and accurate IMP accountability records 
showing the date of receipt and quantity of all supplies of IMP . These records must include 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 100 of 131 
 accurate patient -specific dispensing information including quantity of capsules /bottles 
dispensed, date dispensed , and quantity and date returned (or disposed of).  
At the end of the study , reconciliation must be made between the amount of IMP supplied, 
dispensed and subsequently returned to the sponsor or destroyed at site and any 
discrepancies accounted for .  
Destruction of the IMP at site will only be performed by [CONTACT_787987] . The procedure should be fully documented as outlined 
in the DHA . 
14.1.2.  Cytarabine  and Decitabine  
All patients in Part B2 and Part B5 will receive subcutaneous low-dose cytarabine . 
Name: [CONTACT_788004]: Ara-C  
Active Substance: Cytosine Arabinoside   
Pharmaceutical form: S olution for injection  
Route of administration: Subcutaneous   
Investigational Medicinal Product Status: Non -IMP  
ATC code: L01 BC01  
Cytarabine  will have commercial packaging and labels  in accordance with its marketing 
authori zation . It will be purchased by [CONTACT_257743][INVESTIGATOR_787948] A.  
All patients in Part B3 will receive intravenous decitabine per standard practice.  
Name: [CONTACT_788005]: Dacogen   
Active Substance: Decitabine  (5-aza-2'-deoxycytidine)  
Pharmaceutical  form: Solution for injection  
Route of administration: Intravenous  
Investigational Medicinal Product Status: Non -IMP  
ATC code: L01BC08  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084527] manner according to the current 
marketing authori zation by [CONTACT_239075] . It will be purchased by [CONTACT_257743][INVESTIGATOR_787949] A.  
[IP_ADDRESS].  Cytarabine  and Decitabine Storage  
Cytarabine  and decitabine will be stored in accordance with the specific manufacturer’s SmPC  
or US prescribing information . A copy of the SmPC or US prescribing information for the 
product used should be kept in the BGBC003 Pharmacy file , Investigator Site File and the 
TMF.  
[IP_ADDRESS].  Cytarabine  and Decitabine Accountability  
The investigator /designee must maintain complete and accurate cytarabine  and decitabine 
dispensing logs including the actual dose administered and the date .  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 102 of 131 
 15. Safety Definitions, Monitoring and Reporting  
Safety reporting in this clinical study will be undertaken in accordance with current regulatory 
and national requirements.  
15.1.  Definitions  
The following definitions  are according to the Directive 2001/20/EC.  
15.1.1.  Adverse Event  
An AE is any untoward  medical occurrence in a patient or clinical study subject administered 
a pharmaceutical product and which does not necessarily have a  causal relationship with the 
product . An AE can therefore be  any unfavorable or unintended sign , symptom or disease 
temporally associated with the use of the  IMP whether or not considered related to the IMP . 
This includes any occurrence that is new , an exacerbation of an existing disease (a worsening 
of the character, frequency or severity of a known condition) or abnormal results of diagnostic 
procedures , including clinically significant laboratory test abnormalities.  
Suggested criteria  for the asse ssment of clinical significance for laboratory abnormalities are 
as follows .  
The laboratory abnormality : 
• is clearly consistent with the pattern of leukemia disease or progression;  
• is accompanied by [CONTACT_4659];  
• requires study drug dose modification or interruption or permanent discontinuation of 
study treatment;  
• requires more frequent follow -up assessments, further diagnostic investigation, etc.;  
• requires a change in concomitant medication, therapy, or treatment.  
If the clinically significant laborat ory abnormality is a sign of a disease or syndrome (e.g. 
alkaline phosphatase and bilirubin 5X ULN associated with cholecystitis), only the diagnosis 
(e.g. cholecystitis) needs to be recorded on the AE eCRF. If the clinically significant laboratory 
abnorma lity is not a sign of a disease or syndrome, the abnormality itself should be recorded 
as an AE or SAE on the eCRF. If the laboratory abnormality can be characterized by a precise 
clinical term, the clinical term should be recorded as the AE or SAE . For ex ample, an elevated 
serum potassium level of 7.0 mEq/L should be recorded as “hyperkalemia.”  Observations of 
the same clinically significant laboratory abnormality from visit to visit should not be repeatedly 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 103 of 131 
 recorded as AEs or SAEs on the eCRF, unless the ir severity, seriousness, or etiology 
changes.  
For all AEs, a diagnosis should be recorded on the eCRF rather than individual signs and 
symptoms (e.g. record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases) where ver possible . However, if a constellation of signs and/or 
symptoms cannot be medically characterized as a single syndrome at the time of reporting, 
each individual sign and/or symptom should be recorded as an AE or SAE on the eCRF. If a 
diagnosis is subseq uently established, the reported event term should be updated to reflect 
the medical diagnosis.  
Note that AEs occurring secondary to an initiating event that are separated in time or medically 
significant should be recorded as independent events on the eCRF. For example, if a severe 
gastrointestinal hemorrhage leads to a renal failure, both events should be recorded 
separately on the eCRF.  
A pre -existing medical condition which is present at the start of the study and described in the 
Medical History eCRF, should only be recorded as an AE or SAE if the frequency, severity, or 
character of the condition worsens during the study . When recording such events on the AE 
eCRF, it is important to convey the concept that the pre -existing condition has changed by 
[CONTACT_9672] (e.g. “more frequent headaches”).  
15.1.2.  Adverse Reaction  
An adverse drug reaction (ADR) is defined as  all untoward and unintended responses to an 
IMP related to any dose administered.  The definition implies a reas onable possibility  of a 
causal relationship between the event and the IMP  i.e. there are facts (evidence) or arguments 
to suggest a causal relationship.  
15.1.3.  Serious Adverse Event  
An SAE as defined by [CONTACT_787988] (ICH) is any untoward medical occurrence that meets any 
of the following conditions:  
• Results in death  
• Is life -threatening (i.e. the patient was at risk of death at the time of the event; it does 
not refer to an event which hypothetically might have caused death if it were more 
severe)  
• Requires in -patient hospi[INVESTIGATOR_787950]003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 104 of 131 
 • Results in persistent or significant disability/incapacity  
• Results in a congeni tal anomaly/birth defect  
Important medical events that may not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_787951] a bove , should also be considered serious.  
15.2.  Monitoring and Reporting Events  
15.2.1.  Adverse Events  
Any AE experienced by a patient between  signing the informed consent form (ICF) and [ADDRESS_1084528] resolved to Grade 
≤1, stabilized or returned to baseline .  
15.2.2.  Serious Adverse Events  
Any SAE experienced by a patien t between the time of the first administration of bemcentinib 
and [ADDRESS_1084529] administration is to be recorded on an SAE Report Form as well as 
in the eCRF within 24  hours of knowledge by [CONTACT_709026] , regardless of 
the severity and causality of the event . The exception to this will be patients who experience 
an SAE due to a Screening assessment . Such events should also be reported and will be 
recorded in the CSR . SAEs with a suspected relationship with bemcentinib will be collected 
indefinitely . The SAE Report Form should be  e -mailed to the Syneos  Health Safety and 
Pharmacovigilance Global Safety Mailbox [EMAIL_1604] .  
All SAEs that have not resolved by [CONTACT_2054], or that have not resolved upon the 
patient’s discontinuation from the study, must be followed until any of the following occur:  
• The event resolves  
• The event stabili zes 
• The event returns to baseline status  
• The event can be attributed to agents other than the IMP or to factors unrelated to 
study conduct  
• It becomes unlikely that any additional information can be obtained  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 105 of 131 
 Any event requiring hospi[INVESTIGATOR_18543] (or prolongation of hospi[INVESTIGATOR_18543]) that occurs duri ng the 
course of a patient ’s participation in a clinical study must be reported as an SAE . Exclusions 
to this are hospi[INVESTIGATOR_165433]:  
• For pre -scheduled or routine elective procedures (as long as the qualifying condition 
did not worsen or progress, in the op inion of the investigator , since signing the ICF)  
• For social reasons, in the absence of an AE e.g. for respi[INVESTIGATOR_4594]  
• Due to expected deterioration caused by [CONTACT_388834]  
15.2.3.  All Events  
All events must be assessed to determine the following:  
• If the event meets the criteria for an SAE as defined in Section 15.2.2 
• The severity of the event as defined in Section 15.3.1 
• The relationship to bemcentinib as defined in Section 15.3.2 
15.3.  Safety Classifications  
15.3.1.  Assessment of Severity  
The investigator/designee will rate the severity of each AE according to CTCAE . For each sign 
or symptom, the maximum or high est grade observed since the last visit should be reported . 
If the symptom or event cannot be graded according to CTCAE, the following grade (severity) 
rating guideline will be used:  
Grade [ADDRESS_1084530]’s usual activities  
Grade [ADDRESS_1084531]’s usual activities and may be incapacitating 
or life-threatening  
15.3.2.  Assessment of Causality  
The investigator will assess the causality of the AE with respect to the IMP according to the 
following guidance : 
Unrelated  The Adverse Event is clearly unrelated to bemcentinib  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084532] 
be provided . The causality assessment given by [CONTACT_787989] . If the sponsor disagrees with the investigator’s causality assessm ent, both the 
opi[INVESTIGATOR_787952].  
15.3.3.  Assessment of Expectedness  
An unexpected adverse event  is an event, the nature or severity of which is not consistent with 
the reference safety information (RSI) presented in the IB for the IMP . The responsibility for 
determining expectedness of an ADR falls to the sponsor.  
15.3.4.  Immediate Reporting of Serious Adverse Events  
Expedited safety reporting within this clinical study complies with the ICH Guideline for Clinical 
Safety Data Management: Definitions and Standards for Expedited Reporting (E2A) , 
investigational new drug (IND) application safety reporting (under 21CFR312.32), and with 
applicable local regulatory requirements . 
The sponsor assumes responsibility for appropriate reporting of AEs to the Regulatory 
Authorities  and main Research Ethics Committee s (REC)/Institutional Review Board s (IRB) . 
Although this responsibility can be delegated to the sponsor’s Contract Research organi zation 
(CRO) , the sponsor retains ultimate responsibility for safety reporting .  
All SAEs that are unexpected and associated with the use of the IMP are classified as 
suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) and must be report ed to the main 
REC s/IRBs and Regulatory Authorities  within 7 calendar days if fatal or life threatening, or 
within 15 calendar days if non -life threatening and non -fatal. The sponsor /designee  must also 
report S[LOCATION_003]Rs to all investigational sites.  
Any safety information from other observations that could change the risk -benefit evaluation 
of the IMP should be promptly communicated to the Regulatory Authorities and main 
REC s/IRBs. Any other S[LOCATION_003]Rs associated with the IMP should be reported as soon as the 
sponsor becomes aware of them including S[LOCATION_003]Rs which occur in another clinical study 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 107 of 131 
 conducted by [CONTACT_787990], a publication , 
or which are transmitted to the sponsor by [CONTACT_144299] .  
Other safety issues that also qualify for expedited reporting where they might materially alter 
the current benefit -risk assessment of the IMP (sufficient to consider changes in the 
administration or in the overall conduct of the trial), for instance include:  
• An increase in the rate of occurrence of an expected serious adverse reaction, which 
is judged to be clinically important  
• Post-study S[LOCATION_003]R s that occur after the patient has completed a clinical trial and are 
reported by [CONTACT_68477]  
• New event s relating to the conduct of the trial or the development of the IMP likely to 
affect the safety of the patients , such as:  
o An SAE  which could be associated with the trial procedures and which could 
modify the conduct of the trial  
o A major safety finding (such as carcinogenicity, which differs to the underlying 
disease)  
Expedited reporting is not usually required  for reactions which are s erious but expected,  and 
it is inappropriate to report events that are considered unrelated to the IMP. 
15.3.5.  Annual Safety Updates  
Once a year the sponsor/designee will submit an annual Development Safety Update Report 
(DSUR)  to the Regulatory Authorities and m ain REC s/IRBs that lists all suspected serious 
adverse reactions occurring throughout the time period.  
15.3.6.  Deaths  
The cause of death of a patient  in a clinical study, unless it is associated with disease 
progression, is considered a SAE whether the event is expected or associated with the IMP.  
The reporting periods for SAEs are detailed in Section 15.2.2 . 
15.3.7.  Procedures for Handling Special Situations  
[IP_ADDRESS].  Pregnancy  
As detailed in the inclusion/exclusion criteria, patients  of childbearing potential who are not 
using adequate contraception will not be invited to participate in this study . Female patients of 
childbearing potential must have a negative serum pregnancy test within [ADDRESS_1084533] dose of bemcentinib . In the event of any pregnancies occurring in female patients , or in 
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084534] be reported to the Syneos 
Health Safety and Pharmacovigilance Global Safety mailbox 
[EMAIL_1604]   by [CONTACT_787991] a Pregnancy Notification Form.  
The reporting period for pregnancies will start with the first study -related procedure and end 
[ADDRESS_1084535] patients  whose partners become pregnant can remain in the study . A patient  who 
completes or withdraws from the trial before the full term of their/their partner’s pregnancy will 
be asked to consent to their doctor providing the sponsor with follow -up information c oncerning 
the pregnancy and its outcome.  
15.3.8.  Medical Emergency  
In a medical emergency requiring immediate attention, study staff will apply appropriate 
medical intervention according to standard medical practice . The investigator/ designee should 
contact [CONTACT_787983]’s Medical Monitor  if guidance is needed to manage a cas e particularly if 
the medical emergency is suspected to be related to the IMP . 
[IP_ADDRESS].  Unblinding for a Medical Emergency  
Not applicable.  
15.4.  Investigator’s Safety Responsibilities  
The investigator’s responsibilities include the following:  
• Monitor and record all AEs, including SAEs, regardless of the severity or relationship 
to bemcentinib  
• Determine the seriousness, relationship and severity of each event  
• Determine the onset and resolution of each event  
• Complete an SAE form for each SAE as o utlined in Section 15.2.2 
• Pursue SAE follow -up information actively and persistently  
• Ensure all AE and SAE reports are supported by [CONTACT_787992]  
• Report SAEs to their local REC /IRB, as required by [CONTACT_787993]003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 109 of 131 
 15.5.  Sponsor’s Safety Responsibilities  
The sponsor’s responsibilities include the following:  
• The ongoing safety evaluation of the IMP  
• Reporting of S[LOCATION_003]Rs to the Regulatory Authorities , main R EC/IRB and investigators 
according to required timelines as outlined in Section 15.3.4 
• Submission of  the annual  DSUR  to the Regulatory Authorities and main REC/IRB  
15.6.  Overdose  
Study drug overdose is the accidental or intentional use of the drug in an amount higher than 
the dose being studied. An overdose or incorrect administration of study drug is not an AE 
unless it results in untoward medical effects. An overdose is defined by a boundary of 15% 
above the prescribed dose of any medicinal p roduct.  
Any study drug overdose or incorrect administration of study drug should be noted on the 
Study Drug Administration eCRF. All AEs associated with an overdose or incorrect 
administration of study drug should be recorded on the AE eCRF. If the associa ted AE fulfills 
serious criteria, the event should be reported to the Sponsor immediately (i.e., no more than 
24 hours after learning of the event).  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084536] protocol -defined screening 
procedure . All patients  in the Enrolled Po pulation will be accounted for in patient  disposition . 
Patient disposition will be summari zed by [CONTACT_7169] . Medical history and prior medications 
will be tabulated.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 111 of 131 
 Data from patients who fail screening will not be collected . The exception to this will be  patients 
who experience an SAE due to a Screening assessment . Such events should be reported and 
will be recorded in the CSR.  
16.4.  Safety  
16.4.1.  Analysis Population  
The safety analysis set (SAS) will be defined as all patients  who receive at least one dose of 
bemcentinib . The SAS will be analy zed by [CONTACT_787994] B .  
Patients enrolled to Part A who meet the eligibility criteria for Part B1 and who receive the 
RP2D, may contribute to the Part B1 analysis . 
Any patient who continues treatment with bemcentinib beyond confirmed disease progression 
will be followed for safet y (AEs/SAEs) as well as general condition, performance status etc ., 
as defined in protocol section 13 . 
16.4.2.  Methods of Analysis  
No formal statistical analysis will be performed . AEs will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA) Version [ADDRESS_1084537] administration of bemcentinib . 
Separate listings  will be produced for DLTs, SAEs, discontinuations due to related AEs, and 
events of >Grade [ADDRESS_1084538] results outside the normal range will be individually listed for clinical 
review . Abnormal EC G results will be summarized by [CONTACT_42376] .  
Changes in PR, QT interval and QTc F duration will be analy zed according to administered 
dose and ultimately modelled with corresponding plasma concentrations of bemcentinib when 
available.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 112 of 131 
 Any patient treated with bemcentinib beyond disease progression will be followed for the same 
safety and efficacy assessments as for all other patients enrolled into the study. The data for 
patients treated beyond progression will be presented in both a combined output (with all 
patients) and also a separate output (reflecting a new period of analysis with the data collected 
in this period). All data collected will be included in the study CSR and may be presented at 
congress/symposia.  
16.5.  Efficacy  
16.5.1.  Analysis Population  
The Efficacy Analysis Population will include all subjects who receive >1 dose of bemcentinib 
(Full Analysis Set) . 
Any patient who continues treatment with bemcentinib beyond confirmed disease progression 
will be followed for efficacy assessments (hematology t esting, physical examinations and bone 
marrow biopsy, if clinically indicated), as defined in protocol section 13.  
For the Per Protocol analysis set, the population will be defined as follows:  
Patients that  
• Meet key eligibility criteria, have assessable di sease at baseline  and have at least one 
post-baseline response assessment  
• Have received >1 dose of bemcentinib (and combination agent in Part B2, B3 and B5)  
16.5.2.  Methods of Analysis  
Although all efficacy analysis for this study is to be regarded as essentially exploratory, there 
will be formal hypothesis tests for the objective response rate  (ORR) . These will consist of 
one-sided, within -group tests of proportion of responders for each criterion, against the null 
hypothesis of a response rate <5% (this being the observed response rate under current 
treatment) . Values of P <0.[ADDRESS_1084539] on the safety or efficacy analysis (e.g. do not meet key eligibility 
criteria or do not have evaluable disease for response assessment at baseline) may be 
replaced.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 113 of 131 
 Data relating to efficacy response will be listed and summarized by [CONTACT_347052], 
as appropriate.  
16.6.  Pharmacokinetics  
16.6.1.  Analysis Population  
The Pharmacokinetics Analysis Population will include  all patients who  receive >[ADDRESS_1084540] evaluable PK data available.  
16.6.2.  Methods of Analysis  
The PK parameters listed in Table 15  (but not limited to) will be derived from the relevant 
concentration data of bemcentinib in each part of the study , der ived from a PK model. Full 
details of the PK methodology will be written in a PK Analysis Plan.  
Table 15: Plasma PK parameters  
Cmax The observed maximum plasma concentration after single dose administration  
tmax The time to reach C max  
AUC 0-tau The area under the curve within a dosing interval , calculated by [CONTACT_516048] -log 
down trapezoidal method.  
z The apparent terminal rate constant estimated from individual linear regression 
of the terminal part of the log concentration vs. time curve  
t½ The apparent terminal half-life, calculated by 0.693/ z  
 
 
Where possible, individual, mean and median bemcentinib plasma concentration -time data 
will be presented in tabular and/or graphical form.  
16.7.  Pharmacodynamics  
16.7.1.  Analysis Population  
The Pharmacodynamic Analysis Population will include  all patients who receive >[ADDRESS_1084541] ≥1 pharmacodynamic sample collected for analysis . 
16.7.2.  Methods of Analysis  
All pharmacodynamic biomarkers will be listed and summari zed by [CONTACT_787995] -point 
as appropriate . No formal statistical  analysis will be performed, although descriptive terms will 
be used to describe the results.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 114 of 131 
 16.8.  Safety Monitoring Committee  
No formal statistical interim analyses  are planned.  
Data will be monitored by [CONTACT_4484], in an on -going manner , to assess patient  safety  as outlined 
in Section [IP_ADDRESS] . During Part A, the SMC will be responsible for:  
• Reviewing the safety data from Cycle 1 of each dose cohort to determine whether dose 
escalation can proceed  
• Determining  the MTD prior to commencing Part B  
• Defining the starting dose of bemcentinib to be administered with cytarabine / 
decitabine  in Part B2/Part B3 . 
During the execution of  Part B the SMC  will convene  after every [ADDRESS_1084542] been fully completed (i.e. last patient last visit has been achieved in both parts). 
Enrolment in Part B2 has been completed with a numb er of patients ongoing, whereas Parts 
B1, B4 and B5 continue to enrol l as of 1 7 Mar  2020.  
Independent Data Monitoring Committee (IDMC) has been established since [ADDRESS_1084543] of The Federal Institute for Drugs and Medical Devices (BfArM). During execution 
of the remainder of Parts B1, B2, B4 and B5, patient safety data will be monitored and 
assessed by [CONTACT_787996] -going manner in accordance with the IDMC charter.   
16.9.  Sample Size Considerations  
Part A of t he study follows a conventional algorithm (3+3 patients per dose level) to identify 
the MTD, escalating on 0/3 or 1/6 patients  experiencing a  DLT. Under this design, there is a 
71% chance of escalation if the true but unknown rate of DLT is 20% , and <50% chance of 
escalation if the true but unknown rate of DLT is >30%. The operating characteristics of this 
3+3 design are outlined in Table 16 . 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 115 of 131 
 Table 16: Operating Characteristics of the 3+3 Study Design  
True but Unknown Rate of DLT (%)  Probability of Escalation (%)  
20 71 
30 49 
40 31 
50 17 
60 8 
 
The total sample size of Part A depends upon whether DLT(s) is ex perienced at a given dose 
level (i.e. whether [ADDRESS_1084544] been treated)  and how many dose levels are tested in 
order to reach the MTD . A minimum  of 6- [ADDRESS_1084545] of proportions, comparing an anticipated ORR  
of >20% against the null hypothesis rate of 5%, with power 80% for a  test of size 0.2 . This 
calculation is based on statistical significance at the 0.2 level , since  this will be taken as 
evidence of a trend worthy of further study . Although this is offered as a formal sample size 
calculation , it is acknowledged that for this early -stage study the analyses will be exploratory 
in nature, and that no account has been taken of multiplicity inherent in the assessment of 
several, presumably non -independent criteria , for ORR . 
16.10.  Clinical Study Report  
The results of the study will be presented in an integrated CSR  according to ICH  guidelines.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 116 of 131 
 17. Ethical Requirements  
17.1.  Good Clinical Practice Statement  
The clinical study will be performed in accordance with the protocol, the Declaration of 
Helsinki, ICH Guidelines, GCP, the European Union (EU) Clinical Trials Directive (CTD)  
2001/20/EC Guideline for GCP CPMP/ICH/135/[ADDRESS_1084546] be approved, in wri ting, by [CONTACT_787997] /IRB before 
patient  enrolment commences.  
The following information should be reported to the REC /IRB during the study:  
• All amendments to the research  (substantial and non -substantial amendments)  
• Annual progress reports  
• Individual S[LOCATION_003]Rs  
• DSUR  on an annual basis  
• Urgent Safety Measures  
The investigator /designee  must notify the REC /IRB within 90 days of completion of the study . 
However if the study is terminated prematurely, written explanation of the reason(s) for the 
early termination must be provided within [ADDRESS_1084547] be approved by [CONTACT_787998] /IRB. 
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084548] Data Protection  
Personally identifiable information (PII) i.e. identifiable information from or about an individual 
will not be collected by [CONTACT_456] . The collection and processing of personal data from 
patients  enrolled in this study will be li mited to those data that are necessary to investigate the 
efficacy, safety, tolerability, quality and utility of the IMP used in this study . These data must 
be collected and processed with adequate precautions to ensure confidentiality and 
compliance with applicable data privacy protection laws and regulations .  
The ICF must explain that identifying information will be kept on file and that portions of the 
patient ’s medical records pertinent to the study will be reviewed by [CONTACT_151670] (or their 
desig nees) and possibly by [CONTACT_787999] /IRB for data verification 
purposes .  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 118 of 131 
 18. Administrative Procedures  
18.1.  Quality Assurance  
In compliance with GCP and regulatory requirements, the sponsor/designee, external 
Regulatory Agency and/or REC /IRB may conduct quality assurance (QA) audits at any time 
during or following completion of the study . The investigator  will be expected to coop erate with 
any audit and to provide assistance and documentation (including source data) as requested.  
18.2.  Case Report Form and Source Document Verification  
Electronic CRFs will be provided for recording clinical data . Designated site personnel will 
record dat a in the eCRF for observations, tests and assessments as specified in the protocol . 
The investigator  must permit direct access to designated source documentation (e.g. medical 
records) for the purpose of verifying that the data recorded in the eCRF are con sistent with 
the original source data .  
18.3.  Study Monitoring  
Before a  patient  can be screened for enrolment into the study, the sponsor/designee will 
conduct a study initiation visit to:  
• Determine that the site facilities are adequate  
• Discuss responsibilities with regard to the protocol with the investigator  and study 
team  
• Conduct training on completion of the eCRF and other study related documentation  
• Review study procedures  
During the conduct of the study, the sponsor/designee will provide support to the investigator  
and study team via t elephone/e -mail communication . The sponsor/designee will conduct 
regular site visits, according to applicable ICH and GCP guidelines, to:  
• Confirm the facilities remain acceptable  
• Confirm the site study team are adhering to the protocol and regulatory requirements  
• Confirm that the IMP is being properly maintained and accountability records are 
accurate and current  
• Confirm data are being accurately recorded in the eCRF by [CONTACT_788000]003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 119 of 131 
 18.4.  Notification of Serious Breaches  
In accordance with Regulation 29A of the Medicines for Human Use (Clinical Trials) 
Regulations 2004 and its amendments the sponsor of the trial is responsible for notifying the 
Regulatory Authorities in writing, within 7 da ys, of any serious breach of:  
• The conditions and principles of GCP in connection with the study  
• The protocol relating to the study   
Whilst under investigation, the site is requested to cooperate with the sponsor/designee in 
providing sufficient information to report the breach to the Regulatory  Authorities  where 
required, and in undertaking any corrective and/or preventive action.  
18.5.  Rete ntion of Study Data  
A copy of all records and essential documents must be retained in the study files for a minimum 
of two years following the last approval of the drug in an ICH region and until there are no 
pending or contemplated marketing applications in an ICH region, or a minimum of two years 
have elapsed since the formal discontinuation of the clinical development of the drug . No 
documents should be destroyed without prior written agreement between the sponsor and the 
investigator . 
Should the investi gator  wish to assign the documents to another party or move them to another 
location, the sponsor must be notified . The sponsor will notify the investigator  in writing when 
the study -related documents are no longer needed.  
18.6.  Use of Information and Publicatio n Policy  
All information regarding bemcentinib and the sponsor’s operations (e.g. patent applications, 
formulas, manufacturing processes, basic scientific data, or formulation information) supplied 
by [CONTACT_788001] . This 
confidential information remains the sole property of the sponsor and shall not be disclosed to 
others without the written consent of the sponsor . The investigator  agrees to use this 
information only to perform this study and will not use it for other purposes including 
publications and presentations without the sponsor’s written consent . The full terms of 
confidentiality, intellectual property and publication  policy are detailed in the current Clinical 
Trial Agreement between the sponsor and the site .  
 
BGBC003 v 10.0 (US);  
[ADDRESS_1084549] Research Organi zations  
Monitoring, data management, statistics and programming,  medical writing, auditing and QA 
services will be outsourced to the sponsor’ s CRO  Covance  
Pharmacovigilance services will be outsourced to Syneos Health  
PK and pharmacodynamics analyses will be outsourced to the sponsor’s Bioanalytical 
services vendor.  
18.8.  Changes to the Final Study Protocol  
All protocol amendments must be submitted to the REC /IRB and, if applicable, to the 
Regulatory Authorities . 
Protocol amendments that affect patient safety, the scope of the investigation, or the scientific 
quality of the study should not be implemented without prior Regulatory  Authority /REC /IRB 
approval  (where applicable) , except where necessary to eliminate immediate hazards to the 
patients . 
18.9.  Investigator Responsibilities  
By [CONTACT_12142] , the investigator agrees to:  
• Conduct the study in accordance with the protocol and make change s only after 
notifying the Sponsor, except to protect the safety, rights or welfare of patients  
• Personally conduct or supervise the study  
• Inform any patients enrolled in the study that the drug is being used for investigational 
purposes  
• Ensure that the requirements relating to obtaining informed consent and REC/ IRB 
review and approval meet Federal guidelines, as stated in 21CFR50 and 21CFR56  
• Report to the Spon sor any AEs that occur during the course of the study, in accordance 
with 21CFR312. 32, as well as ICH guidelines  
• Have read and understood the IB for bemcentinib , including potential risks and side 
effects of the drug  
• Ensure that all associates, colleagues and employees assisting in the conduct of the 
study are informed about their obligations in meeting the above commitments  
• Maintain adequate and accurate records, in accordance with 21CFR312.62 and to 
make those records available for inspection by [CONTACT_212934], their designated 
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 121 of 131 
 representative,  relevant Regulatory Authorit ies/REC/IRB  or any agency authorized by 
[CONTACT_2371] 
• Ensure that a REC/ IRB that complies with the requirements of 21CFR56 will be 
responsible for initial and continuing review and approval of the clin ical study  
• Report promptly to the REC/ IRB and the sponsor all changes in the research activity 
and all unanticipated problems involving risks to subjects or others (to include protocol 
amendments and IND safety reports)  
• Not make any changes in the research  study without approval, except when necessary 
to eliminate hazards to the subject/subjects  
• Comply with all other requirements regarding the obligations of the clinical 
investigators and all other pertinent requirements listed in 21CFR312  
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 122 of 131 
 19. References  
Ben-Batalla I, Schultze A, Wroblewski M, et al., AXL a prognostic and therapeutic target in 
acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow 
stroma . Blood  (2013) 122 (14): 2443 –2452 . 
Cheson BD, Bennett JM, Kopecky KJ, et al., Revised recommendations of the International 
Working Group for Diagnosis, Standardisation of Response Criteria, Treatment Outcomes and 
Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin  Oncol  (2003) 
21(24): 4642 –[ADDRESS_1084550], Bennett JM et al ., Clinical application and proposal for 
modification of the International Working Group (IWG) response criteria in myelodysplasia. 
Blood  (2006) 108 (2): 419 –425. 
Döhner  H, Estey E, Grimwade D, et al., Diagnosis and management of AML in adults: [ADDRESS_1084551] recommendations from an international expert panel. Blood  (2017) 129(4): 424 -447. 
Oken MM, Creech RH, Tormey DC, et al. , Toxicity and response criteria of the Eastern 
Coop erative Oncology Group. Am J Clin Oncol  (1982) 5 (6): 649 –655. 
Whitman  SP, Kohlschmidt J, Maharry K,  et al., Gas6 expression identifies high -risk AML 
patients: potential implications for therapy . Leukemia  (2013) Dec 11. doi: 
10.1038/leu.2013.371. [Epub ahead of print] . 
The Criteria Committee of the [LOCATION_001] Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels.  (1994).  (9th ed.). [LOCATION_011]: Little, Brown 
& Co. 253 –256. 
 
 
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 123 of 131 
 20. Appendices  
Appendix 1: Eastern Cooperative Oncology Group (ECOG) Performance Status  
 
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about m ore than 50% of waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed 
or chair  
5 Dead  
From Oken et al., 1982  with credit to the ECOG Chair Robert Comis M.D  
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 124 of 131 
 Appendix 2: The [LOCATION_001] Heart Association (NYHA) Functional Classification 
in a Patient with Heart Disease  
 
Overview: The [LOCATION_001] Heart Association (NYHA) developed a functional classification for 
patients with heart disease.  
Patients: Heart disease must be present.  
Parameters:  
1) Limitations on physical activity  
2) Symptoms (undue fatigue palpi[INVESTIGATOR_144270] /or anginal pain) with ordinary 
physical activity  
3) Status at rest  
 
Limitations on 
Physical Activity  Symptoms with Ordinary 
Physical Activity  Status at Rest  Class  
none  none  comfortable  I  
slight  symptomatic with ordinary 
activities  comfortable  II  
marked  symptomatic at less than 
ordinary levels of activity  comfortable  III  
unable to perform 
any activity  discomfort with any activity  symptomatic at rest  IV  
From The Criteria Committee of the [LOCATION_001] Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels.  (1994).  (9th ed.). [LOCATION_011]: Little, Brown & Co. 
253 – 256 
 
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 125 of 131 
 Appendix 3: Drugs Associated with  a Risk of QT Prolongation and Cardiac 
Arrhythmias  
 
For any concomitant medication, please check the following website for the drug’s Torsades 
de Pointes (TdP) risk: https://crediblemeds.org/oncosupport/ . Drugs with known TdP risk 
should be avoided. For drugs with a conditional risk, please review the product label and 
correct any abnormalities, e.g. hypokalemia.  
 
Known Risk of TdP  Substantial evidence supports the conclusion that these drugs prolong the 
QT inter val AND are clearly associated with a risk of TdP, even when taken 
as directed in official labelling.  
Possible Risk of TdP  Substantial evidence supports the conclusion that these drugs can cause 
QT prolongation BUT there is insufficient evidence at this t ime that these 
drugs, when used as directed in official labelling, are associated with a risk 
of causing TdP.  
Conditional Risk of 
TdP Substantial evidence supports the conclusion that these drugs are 
associated with a risk of TdP BUT only under certain conditions (e.g. 
excessive dose, hypokalemia, congenital long QT or by [CONTACT_95712] a drug -
drug interaction that results in excessive QT interval prolongation)  
 
Generic Name  [CONTACT_144312]/Pacerone  
Anagrelide  Agrylin®, Xagrid®  
Arsenic trioxide  Trisenox  
Astemizole  Hismanal  
Azithromycin  Zithromax®, Zmax®  
Bepridil  Vascor  
Chlorquine  Arelan  
Chlorpromazine  Thorazine  
Cisapride  Propulsid  
Citalopram  Celexa®, Cipramil®  
Clarithromycin  Biaxin  
Cocaine  Cocaine  
Disopyramide  Norpace  
Dofetilide  Tikosyn  
Domperidone  Motilium  
Dronedarone  Multaq®  
Droperidol  Inapsine  
Erythromycin  Erythrocin/E.E.S.  
Escitalopram  Cipralex®, Lexapro®  
Flecainide  Tambocor®, Almarytm®  
Halofantrine  Halfan  
Haloperidol  Haldol  
Ibutilide  Covert  
Levomethadyl  Orlaam  
Mesoridazine  Serentil  
Methadone  Methadose/Dolophine  
Moxifloxacin  Avelox  
Ondansetron  Zofran®, Anset®  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 126 of 131 
 Petamidine  NebuPent/Pentam  
Pi[INVESTIGATOR_144271]/Procan  
Propofol  Diprivan  
Quinidine  Cardioquin/Quinaglute  
Sevoflurane  Ulane®, Sojourn®  
Sotalol  Betapace  
Sparfloxacin  Zagam  
Sulpi[INVESTIGATOR_144272]®, Dolmatil®  
Terfenadine  Seldane  
Thioridazine  Mellaril  
Vandetanib  Zactima  
 
Woosley RL, Heise CW , Gallo T, Tate J, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs 
List, [Accession Date], AZCERT, Inc. [ADDRESS_1084552]., Oro Valley, AZ [ZIP_CODE]   
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 127 of 131 
 Appendix 4: CYP3A4 Substrates  
 
Examples of CYP3A4 substrates are provided below . For most up -to-date information on 
CYP3A4 substrates, please check the Drug Interactions Flockhart Table™  
https://drug -interactions.medicine.iu.edu/Main -Table.aspx .  
 
University of Indiana CYP3A4, 5, 7 P450 Drug Interactions Abbreviated "Clinically 
Relevant" Table of Substrates  
 
Macrolide antibiotics:  HIV Antivirals:  HMG CoA Reductase 
Inhibitors:  
clarithromycin  indinavir  atorvastatin  
erythromycin (not 3A5)  ritonavir  lovastatin  
NOT azithromycin  saquinavir  NOT pravastatin  
telithromycin  nevirapi[INVESTIGATOR_787953]-arrhythmics:  Prokinetics:   
quinidine→3 -OH  cisapride  Others:  
  alfentanyl  
Benzodiazepi[INVESTIGATOR_1651]:  Antihistamines:  aripi[INVESTIGATOR_787954]→3OH  chlorpheniramine  buspi[INVESTIGATOR_787955]:  gleevec  
 amlodipi[INVESTIGATOR_787956]:  diltiazem  pi[INVESTIGATOR_787957] (FK506)  nifedipi[INVESTIGATOR_787958]-5 Inhibitors:  verapamil  vincristine  
sildenafil   diergotamine & ergotamine  
tadalafil   fentanyl  
vardenafil    
Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School 
of Medicine (2007). "/clinpharm/ddis/clinical -table/" Accessed 20 October 2016.  
  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 128 of 131 
 Appendix 5: Modified International Working Group Response Criteria in Acute 
Myeloid Leukemia ( Cheson, 2003 , Döhner, 2017)  
 
IWG Response 
Criteria in AML  Bone Marrow 
Blasts/Myeloblast  Circulating 
or Peripheral 
Blood 
Blastsa  Absolute 
Neutrophil 
Count  Platelet 
Count  EMD  
Morphologic 
Complete 
Remission  CR <5% and no 
myeloblasts with 
Auer rods  None  ≥1.0 x 109/L 
or ≥1,000/μL  ≥100 x 109/L 
or 
≥100,000/μL  None  
CR with 
Incomplete 
Blood 
Count 
Recovery  CRi <5% and no 
myeloblasts with 
Auer rods  None  <1.0 x 109/L 
or <1,000/μL  <100 x 
109/L or 
<100,000/μL  None  
Morphologic 
leukemia -
free state  MLFS  <5% and no 
myeloblasts with 
Auer rodsb 
 No hematologic recovery required  None  
Partial 
Remission  PR Decrease of 
myeloblasts % to 
5% to 25% and 
decrease of 
pretreatment 
myeloblast % by [CONTACT_12697] 50%  All hematologic criteria of CR   
Unchanged  UN  Absence of CR, CRi or PR and criteria for PD not met  
Progressi ve 
Diseasec  PD >50% increase in 
myeloblasts over 
the pretreatment 
value (a minimum 
15% increase is 
required if <30% 
myeloblasts 
pretreatment)  >50% 
increase in 
PB to >25 × 
109/L or >25 
000/μLd    New 
EMD 
disease  
a. PBs are quantified as an automated WBC times percentage of blasts by [CONTACT_788002] (100 
cells) per standard clinical laboratory procedures.  
b. BM examination should not be aplastic, and have at least [ADDRESS_1084553] 
10% 
c. PD is usually accompanied by a decline in ANC and platelets, increased transfusion requirement 
and decline in performance status and increase in symptoms.  
d. Certain targeted therapi[INVESTIGATOR_787959] a differentiation syndrome, that is, a transient increase in  
the percentage of BM blasts (myeloblasts) and an absolute increase in PBs; in the setting of therapy 
with such compounds, an increase in blasts may not necessarily indicate PD.  
Abbreviations: AML, acute myeloid leukemia, ANC, Absolute Neutrophil Count; BL, EMD, Extramedullary 
Disease; IWG, International Working Group, PB, Peripheral Blood Blast; WBC, White Blood Cell.  
 
References  
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised Recommendations of the International Working 
Group for Diagnosis, Standardisation of Response Criteria, treatment Outcomes and Reporting Standards 
for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 21 (24): 4642 – 4649.  
• Döhner  H, Estey E, Grimwade D, et al . Diagnosis and management of AML in adults: [ADDRESS_1084554] 
recommendations from an international expert panel. Blood (2017) Jan 26; 129(4): 424 –447.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 129 of 131 
 Appendix 6: International Working Group Response Criteria in Myelodysplastic 
Synd romes (Cheson, 2006)  
 
Category A: Altering the natural history of disease  
IWG 
Response 
Criteria in 
MDS  Bone Marrowa  Peripheral Blooda  Additional 
Considerations  
Complete 
Remission 
(CR)  ≤5% myeloblasts with 
normal maturation of all cell 
lines with no evidence for 
dysplasiab Normalization of blood 
counts as defined by:  
  
• Hb ≥11g/dL (not 
supported by [CONTACT_788003])  
• Platelets ≥100 x 109/L 
or 100,000/μL (not 
supported by [CONTACT_27752])  
• Neutrophils ≥1.5 x 
109/L or 1,500/μL (not 
supported by G -CSF)  
• PB 0%  
 Responses to be 
confirmed in two 
successive 
assessments; 
response parameters 
in peripheral blood 
needs to be 
maintained for at 
least 6 weeks.  
Partial 
Remission 
(PR)  All CR criteria met if 
abnormal before treatment 
except for:  
• Myeloblasts decrease 
by 50% or more over 
pretreatment value but still 
>5%, or  
• Less advanced FAB or 
IPPS category compared to 
pretreatment value  
 Hematologic improvement  Absolute values must 
last at least 6 weeks.  
Marrow CR  ≤5% myeloblasts and 
decrease by ≥50% over 
pretreatment value  If hematologic improved, 
these should be noted in 
addition to marrow CR 
(see Category B).  
  
Stable 
Disease (SD)  Failure to achieve at least 
PR, but no evidence of PD 
for at least 3 treatment 
cycles.  
   
Progressive 
Disease  (PD)  • For patients with less 
than 5% myeloblasts: a 
50% or more increase in 
myeloblasts to more than 
5% myeloblasts.  
• For patients with 5% to 
10% myeloblasts: a 50% or 
more increase to more than 
10% myeloblasts.  Myeloblast increase plus 
at least one of the 
following:  
• ≥50% decrease in ANC 
or platelets  
• Reduction in Hb by 
≥2g/dL  
• Transfusion 
dependence.  Death during 
treatment  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 130 of 131 
 • For patients with 10% to 
20% myeloblasts: a 50% o r 
more increase to more than 
20% myeloblasts.  
• For patients with 20% to 
30% myeloblasts: a 50% or 
more increase to more than 
30% myeloblasts.   
Relapse after 
CR or PR  Relapse is characterized by [CONTACT_37408]:  
• Return to pretreatment myeloblasts percentage  
• ≥50% decrease in ANC or platelets  
Reduction in Hb by ≥2g/dL or transfusion dependence.  
Disease 
transformation  Transformation to AML (30% or more blasts).  
Category B: Hematologic Improvement (HI)  
 Hematopoietic Lineage  Response Criteria  Definitiona 
 Erythroid (HI -E)  
 Major response  
 For patients with 
pretreatment Hb<11 
g/dL, greater than 2 
g/dL increase in Hb; 
for RBC transfusion -
dependent patients, 
transfusion 
independence.  
  Minor response  
 For patients with 
pretreatment Hb <11 
g/dL, 1 to 2 g/dL 
increase in Hb; for 
RBC transfusion -
dependent patients, 
50% decrease in 
transfusion 
requirements.  
 Platelet (HI -P)  
 Major response  
 For patients with 
pretreatment PLT 
counts of <100 x 
109/L or 100,000/μL, 
an absolute increase 
of 30 x 109/L or 
30,000/μL or more; 
for PLT transfusion -
dependent patients, 
stabilization of PLT 
counts and PLT 
transfusion 
independence.  
 
BGBC003 v 10.0 (US);  
14 July 2021   CONFIDENTIAL  Page 131 of 131 
   Minor response  
 For patients with 
pretreatment PLT 
counts <100 x 109/L 
or 100,000/μL, a 50% 
or more increase in 
PLT count with a net 
increase >10 x 109/L 
or 10,000/μL but less 
than 30 x 109/L or 
30,000/μL.  
 Neutrophil (HI -N)  
 Major response  
 For ANC <1.5 x 109/L 
or 1,500/μL before 
therapy, ANC 
increase of at least a 
100%, or an absolute 
increase of more than 
0.5 x 109/L or 500/μL, 
whichever is greater.  
  Minor response  
 For ANC less than 
1.5 x 109/L or 
1,500/μL before 
therapy, ANC 
increase of at least 
100%, but absolute 
increase less than 0.5 
x 109/L or 500/μL.  
Category C: Cytogenetic Response (CRc)b 
 Major CRc  No detectable cytogenetic abnormality, if preexisting 
abnormality was present.  
 
 Minor CRc  ≥50% reduction of abnormal metaphases  
 
a. Improvements in BM and PB must be based on ≥2 successive assessments; response in PBN 
must be maintained for at least [ADDRESS_1084555] been examined . For 
cytogenetic response, 20 metaphases are optimal, but not necessary, to define the degree of 
cytogenetic response . FISH to assess changes in a specific cytogenetic abnormality is 
acceptable.  
Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; EPO, erythropoietin; G -
CSF, FAB, French -American -British (classification system); IPPS, International Prognostic Scoring 
System; granulocyte colony stimulating factor; Hb, hemoglobin; IWG, International Working Gro up; 
MDS, myelodysplastic syndrome; PB, peripheral blast; PLT, platelet; RBC, red blood cell.  
 
Reference  
Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the 
International Working Group (IWG) response criteria in m yelodysplasia. Blood. 2006; 108:419 -425. 